Complex pharmacology of free fatty acid receptors

Chemical Reviews

Volumn 117, Issue 1, 2017, Pages 67-110

  Milligan, Graeme ^a   Shimpukade, Bharat ^b   Ulven, Trond ^b   Hudson, Brian D ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES;

ALLOSTERIC MODULATION; DRUG TARGETS; FREE FATTY ACID; G PROTEIN COUPLED RECEPTORS; INFLAMMATORY DISEASE; INVERSE AGONISM; THERAPEUTIC POTENTIALS;

FATTY ACIDS;

FATTY ACID; FLUORESCENT DYE; G PROTEIN COUPLED RECEPTOR; LIGAND;

ALLOSTERISM; ANIMAL; CHEMISTRY; DRUG EFFECTS; HUMAN; METABOLISM;

ALLOSTERIC REGULATION; ANIMALS; FATTY ACIDS, NONESTERIFIED; FLUORESCENT DYES; HUMANS; LIGANDS; RECEPTORS, G-PROTEIN-COUPLED;

EID: 85019400139     PISSN: 00092665     EISSN: 15206890     Source Type: Journal    
DOI: 10.1021/acs.chemrev.6b00056     Document Type: Review

References (402)

1. Cornall, L. M.; Mathai, M. L.; Hryciw, D. H.; McAinch, A. J. GPR120 Agonism as a Countermeasure against Metabolic Diseases. Drug Discovery Today 2014, 19, 670-679.
2. Dranse, H. J.; Kelly, M. E.; Hudson, B. D. Drugs or Diet?-Developing Novel Therapeutic Strategies Targeting the Free Fatty Acid Family of GPCRs. Br. J. Pharmacol. 2013, 170, 696-711.
3. Hara, T.; Kashihara, D.; Ichimura, A.; Kimura, I.; Tsujimoto, G.; Hirasawa, A. Role of Free Fatty Acid Receptors in the Regulation of Energy Metabolism. Biochim. Biophys. Acta, Mol. Cell Biol. Lipids 2014, 1841, 1292-1300.
4. Hudson, B. D.; Ulven, T.; Milligan, G. The Therapeutic Potential of Allosteric Ligands for Free Fatty Acid Sensitive GPCRs. Curr. Top. Med. Chem. 2013, 13, 14-25.
5. Kim, S.; Kim, J. H.; Park, B. O.; Kwak, Y. S. Perspectives on the Therapeutic Potential of Short-Chain Fatty Acid Receptors. BMB Rep. 2014, 47, 173-178.
6. Milligan, G.; Ulven, T.; Murdoch, H.; Hudson, B. D. G-Protein-Coupled Receptors for Free Fatty Acids: Nutritional and Therapeutic Targets. Br. J. Nutr. 2014, 111 (Suppl 1), S3-S7.
7. Watterson, K. R.; Hudson, B. D.; Ulven, T.; Milligan, G. Treatment of Type 2 Diabetes by Free Fatty Acid Receptor Agonists. Front. Endocrinol. (Lausanne, Switz.) 2014, 5, 137.
8. Bhardwaj, S.; Passi, S. J.; Misra, A. Overview of Trans Fatty Acids: Biochemistry and Health Effects. Diabetes Metab. Syndr. 2011, 5, 161-164.
9. Tardy, A. L.; Morio, B.; Chardigny, J. M.; Malpuech-Brugere, C. Ruminant and Industrial Sources of Trans-Fat and Cardiovascular and Diabetic Diseases. Nutr. Res. Rev. 2011, 24, 111-117.
10. Shevchenko, A.; Simons, K. Lipidomics: Coming to Grips with Lipid Diversity. Nat. Rev. Mol. Cell Biol. 2010, 11, 593-598.
11. Sokol, E.; Ulven, T.; Faergeman, N. J.; Ejsing, C. S. Comprehensive and Quantitative Profiling of Lipid Species in Human Milk, Cow Milk and a Phospholipid-Enriched Milk Formula by GC and MS/MS. Eur. J. Lipid Sci. Technol. 2015, 117, 751-759.
12. Dehairs, J.; Derua, R.; Rueda-Rincon, N.; Swinnen, J. V. Lipidomics in Drug Development. Drug Discovery Today: Technol. 2015, 13, 33-38.
13. Ulven, T.; Christiansen, E. Dietary Fatty Acids and Their Potential for Controlling Metabolic Diseases through Activation of FFA4/GPR120. Annu. Rev. Nutr. 2015, 35, 239-263.
14. Yates, C. M.; Calder, P. C.; Ed Rainger, G. Pharmacology and Therapeutics of Omega-3 Polyunsaturated Fatty Acids in Chronic Inflammatory Disease. Pharmacol. Ther. 2014, 141, 272-282.
15. Weylandt, K. H.; Chiu, C. Y.; Gomolka, B.; Waechter, S. F.; Wiedenmann, B. Omega-3 Fatty Acids and Their Lipid Mediators: Towards an Understanding of Resolvin and Protectin Formation. Prostaglandins Other Lipid Mediators 2012, 97, 73-82.
16. Murphy, R. C.; Gijon, M. A. Biosynthesis and Metabolism of Leukotrienes. Biochem. J. 2007, 405, 379-395.
17. Lands, W. E. Biosynthesis of Prostaglandins. Annu. Rev. Nutr. 1991, 11, 41-60.
18. Woodward, D. F.; Jones, R. L.; Narumiya, S. International Union of Basic and Clinical Pharmacology. LXXXIII: Classification of Prostanoid Receptors, Updating 15 Years of Progress. Pharmacol. Rev. 2011, 63, 471-538.
19. Back, M.; Powell, W. S.; Dahlen, S. E.; Drazen, J. M.; Evans, J. F.; Serhan, C. N.; Shimizu, T.; Yokomizo, T.; Rovati, G. E. Update on Leukotriene, Lipoxin and Oxoeicosanoid Receptors: IUPHAR Review 7. Br. J. Pharmacol. 2014, 171, 3551-3574.
20. Alexander, S. P.; Benson, H. E.; Faccenda, E.; Pawson, A. J.; Sharman, J. L.; Spedding, M.; Peters, J. A.; Harmar, A. J.; Collaborators, C. The Concise Guide to Pharmacology 2013/14: G Protein-Coupled Receptors. Br. J. Pharmacol. 2013, 170, 1459-1581.
21. Lee, J. H.; O'Keefe, J. H.; Lavie, C. J.; Harris, W. S. Omega-3 Fatty Acids: Cardiovascular Benefits, Sources and Sustainability. Nat. Rev. Cardiol. 2009, 6, 753-758.
22. Carpentier, Y. A.; Portois, L.; Malaisse, W. J. N-3 Fatty Acids and the Metabolic Syndrome. Am. J. Clin. Nutr. 2006, 83, 1499S-1504S.
23. Aranceta, J.; Perez-Rodrigo, C. Recommended Dietary Reference Intakes, Nutritional Goals and Dietary Guidelines for Fat and Fatty Acids: A Systematic Review. Br. J. Nutr. 2012, 107 (Suppl 2), S8-S22.
24. de Souza, R. J.; Mente, A.; Maroleanu, A.; Cozma, A. I.; Ha, V.; Kishibe, T.; Uleryk, E.; Budylowski, P.; Schunemann, H.; Beyene, J.; et al. Intake of Saturated and Trans Unsaturated Fatty Acids and Risk of All Cause Mortality, Cardiovascular Disease, and Type 2 Diabetes: Systematic Review and Meta-Analysis of Observational Studies. BMJ. 2015, 351, h3978.
25. Yore, M. M.; Syed, I.; Moraes-Vieira, P. M.; Zhang, T.; Herman, M. A.; Homan, E. A.; Patel, R. T.; Lee, J.; Chen, S.; Peroni, O. D.; et al. Discovery of a Class of Endogenous Mammalian Lipids with Anti-Diabetic and Anti-Inflammatory Effects. Cell 2014, 159, 318-332.
26. Roodhart, J. M.; Daenen, L. G.; Stigter, E. C.; Prins, H. J.; Gerrits, J.; Houthuijzen, J. M.; Gerritsen, M. G.; Schipper, H. S.; Backer, M. J.; van Amersfoort, M.; et al. Mesenchymal Stem Cells Induce Resistance to Chemotherapy through the Release of Platinum-Induced Fatty Acids. Cancer Cell 2011, 20, 370-383.
27. Daenen, L. G.; Cirkel, G. A.; Houthuijzen, J. M.; Gerrits, J.; Oosterom, I.; Roodhart, J. M.; van Tinteren, H.; Ishihara, K.; Huitema, A. D.; Verhoeven-Duif, N. M.; et al. Increased Plasma Levels of Chemoresistance-Inducing Fatty Acid 16:4(N-3) after Consumption of Fish and Fish Oil. JAMA Oncol 2015, 1, 350-358.
28. Ley, R. E.; Turnbaugh, P. J.; Klein, S.; Gordon, J. I. Microbial Ecology: Human Gut Microbes Associated with Obesity. Nature 2006, 444, 1022-1023.
29. Karlsson, F.; Tremaroli, V.; Nielsen, J.; Backhed, F. Assessing the Human Gut Microbiota in Metabolic Diseases. Diabetes 2013, 62, 3341-3349.
30. Flint, H. J.; Scott, K. P.; Louis, P.; Duncan, S. H. The Role of the Gut Microbiota in Nutrition and Health. Nat. Rev. Gastroenterol. Hepatol. 2012, 9, 577-589.
31. Sanz, Y.; Santacruz, A.; De Palma, G. Insights into the Roles of Gut Microbes in Obesity. Interdiscip. Perspect. Infect. Dis. 2008, 2008, 1-9.
32. den Besten, G.; van Eunen, K.; Groen, A. K.; Venema, K.; Reijngoud, D. J.; Bakker, B. M. The Role of Short-Chain Fatty Acids in the Interplay between Diet, Gut Microbiota, and Host Energy Metabolism. J. Lipid Res. 2013, 54, 2325-2340.
33. Lagerstrom, M. C.; Schioth, H. B. Structural Diversity of G Protein-Coupled Receptors and Significance for Drug Discovery. Nat. Rev. Drug Discovery 2008, 7, 339-357.
34. Reiter, E.; Ahn, S.; Shukla, A. K.; Lefkowitz, R. J. Molecular Mechanism of Beta-Arrestin-Biased Agonism at Seven-Transmembrane Receptors. Annu. Rev. Pharmacol. Toxicol. 2012, 52, 179-197.
35. Flordellis, C. S. The Plasticity of the 7TMR Signaling Machinery and the Search for Pharmacological Selectivity. Curr. Pharm. Des. 2012, 18, 145-160.
36. Jacoby, E.; Bouhelal, R.; Gerspacher, M.; Seuwen, K. The 7 TM G-Protein-Coupled Receptor Target Family. ChemMedChem 2006, 1, 760-782.
37. Heilker, R.; Wolff, M.; Tautermann, C. S.; Bieler, M. G-Protein-Coupled Receptor-Focused Drug Discovery Using a Target Class Platform Approach. Drug Discovery Today 2009, 14, 231-240.
38. Garland, S. L. Are GPCRs Still a Source of New Targets? J. Biomol. Screening 2013, 18, 947-966.
39. Tautermann, C. S. GPCR Structures in Drug Design, Emerging Opportunities with New Structures. Bioorg. Med. Chem. Lett. 2014, 24, 4073-4079.
40. Shonberg, J.; Kling, R. C.; Gmeiner, P.; Lober, S. GPCR Crystal Structures: Medicinal Chemistry in the Pocket. Bioorg. Med. Chem. 2015, 23, 3880-3906.
41. Lee, S. M.; Booe, J. M.; Pioszak, A. A. Structural Insights into Ligand Recognition and Selectivity for Classes A, B, and C GPCRs. Eur. J. Pharmacol. 2015, 763, 196-205.
42. Jazayeri, A.; Dias, J. M.; Marshall, F. H.; From, G. Protein-Coupled Receptor Structure Resolution to Rational Drug Design. J. Biol. Chem. 2015, 290, 19489-19495.
43. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; Fox, B. A.; Le Trong, I.; Teller, D. C.; Okada, T.; Stenkamp, R. E.; et al. Crystal Structure of Rhodopsin: A G Protein-Coupled Receptor. Science 2000, 289, 739-745.
44. Mustafi, D.; Palczewski, K. Topology of Class A G Protein-Coupled Receptors: Insights Gained from Crystal Structures of Rhodopsins, Adrenergic and Adenosine Receptors. Mol. Pharmacol. 2009, 75, 1-12.
45. Zhao, Q.; Wu, B. L. Ice Breaking in GPCR Structural Biology. Acta Pharmacol. Sin. 2012, 33, 324-334.
46. Ghosh, E.; Kumari, P.; Jaiman, D.; Shukla, A. K. Methodological Advances: The Unsung Heroes of the GPCR Structural Revolution. Nat. Rev. Mol. Cell Biol. 2015, 16, 69-81.
47. Blois, T. M.; Bowie, J. U. G-Protein-Coupled Receptor Structures Were Not Built in a Day. Protein Sci. 2009, 18, 1335-1342.
48. Venkatakrishnan, A. J.; Deupi, X.; Lebon, G.; Tate, C. G.; Schertler, G. F.; Babu, M. M. Molecular Signatures of G-Protein-Coupled Receptors. Nature 2013, 494, 185-194.
49. Wheatley, M.; Wootten, D.; Conner, M. T.; Simms, J.; Kendrick, R.; Logan, R. T.; Poyner, D. R.; Barwell, J. Lifting the Lid on GPCRs: The Role of Extracellular Loops. Br. J. Pharmacol. 2012, 165, 1688-1703.
50. Adams, M. N.; Ramachandran, R.; Yau, M. K.; Suen, J. Y.; Fairlie, D. P.; Hollenberg, M. D.; Hooper, J. D. Structure, Function and Pathophysiology of Protease Activated Receptors. Pharmacol. Ther. 2011, 130, 248-282.
51. Conner, A. C.; Simms, J.; Hay, D. L.; Mahmoud, K.; Howitt, S. G.; Wheatley, M.; Poyner, D. R. Heterodimers and Family-B GPCRs: RAMPs, CGRP and Adrenomedullin. Biochem. Soc. Trans. 2004, 32, 843-846.
52. Woolley, M. J.; Conner, A. C. Comparing the Molecular Pharmacology of CGRP and Adrenomedullin. Curr. Protein Pept. Sci. 2013, 14, 358-374.
53. Booe, J. M.; Walker, C. S.; Barwell, J.; Kuteyi, G.; Simms, J.; Jamaluddin, M. A.; Warner, M. L.; Bill, R. M.; Harris, P. W.; Brimble, M. A.; et al. Structural Basis for Receptor Activity-Modifying Protein-Dependent Selective Peptide Recognition by a G Protein-Coupled Receptor. Mol. Cell 2015, 58, 1040-1052.
54. Milligan, G. The Prevalence, Maintenance, and Relevance of G Protein-Coupled Receptor Oligomerization. Mol. Pharmacol. 2013, 84, 158-169.
55. Ferre, S.; Casado, V.; Devi, L. A.; Filizola, M.; Jockers, R.; Lohse, M. J.; Milligan, G.; Pin, J. P.; Guitart, X. G Protein-Coupled Receptor Oligomerization Revisited: Functional and Pharmacological Perspectives. Pharmacol. Rev. 2014, 66, 413-434.
56. Kern, A.; Mavrikaki, M.; Ullrich, C.; Albarran-Zeckler, R.; Brantley, A. F.; Smith, R. G. Hippocampal Dopamine/DRD1 Signaling Dependent on the Ghrelin Receptor. Cell 2015, 163, 1176-1190.
57. Moreno, J. L.; Miranda-Azpiazu, P.; Garcia-Bea, A.; Younkin, J.; Cui, M.; Kozlenkov, A.; Ben-Ezra, A.; Voloudakis, G.; Fakira, A. K.; Baki, L.; et al. Allosteric Signaling through an mGlu2 and 5-HT2a Heteromeric Receptor Complex and Its Potential Contribution to Schizophrenia. Sci. Signaling 2016, 9, ra5.
58. Dimond, P.; Carlson, K.; Bouvier, M.; Gerard, C.; Xu, L.; Covic, L.; Agarwal, A.; Ernst, O. P.; Janz, J. M.; Schwartz, T. W.; et al. G Protein-Coupled Receptor Modulation with Pepducins: Moving Closer to the Clinic. Ann. N. Y. Acad. Sci. 2011, 1226, 34-49.
59. Zhang, P.; Covic, L.; Kuliopulos, A. Pepducins and Other Lipidated Peptides as Mechanistic Probes and Therapeutics. Methods Mol. Biol. 2015, 1324, 191-203.
60. Kruse, A. C.; Ring, A. M.; Manglik, A.; Hu, J.; Hu, K.; Eitel, K.; Hubner, H.; Pardon, E.; Valant, C.; Sexton, P. M.; et al. Activation and Allosteric Modulation of a Muscarinic Acetylcholine Receptor. Nature 2013, 504, 101-106.
61. Davie, B. J.; Christopoulos, A.; Scammells, P. J. Development of M1Machr Allosteric and Bitopic Ligands: Prospective Therapeutics for the Treatment of Cognitive Deficits. ACS Chem. Neurosci. 2013, 4, 1026-1048.
62. Valant, C.; Robert Lane, J.; Sexton, P. M.; Christopoulos, A. The Best of Both Worlds? Bitopic Orthosteric/Allosteric Ligands of G Protein-Coupled Receptors. Annu. Rev. Pharmacol. Toxicol. 2012, 52, 153-178.
63. Mohr, K.; Schmitz, J.; Schrage, R.; Trankle, C.; Holzgrabe, U. Molecular Alliance-from Orthosteric and Allosteric Ligands to Dualsteric/Bitopic Agonists at G Protein Coupled Receptors. Angew. Chem., Int. Ed. 2013, 52, 508-516.
64. Mohr, K.; Trankle, C.; Kostenis, E.; Barocelli, E.; De Amici, M.; Holzgrabe, U. Rational Design of Dualsteric GPCR Ligands: Quests and Promise. Br. J. Pharmacol. 2010, 159, 997-1008.
65. Hill, S. J.; May, L. T.; Kellam, B.; Woolard, J. Allosteric Interactions at Adenosine a(1) and a(3) Receptors: New Insights into the Role of Small Molecules and Receptor Dimerization. Br. J. Pharmacol. 2014, 171, 1102-1113.
66. Smith, N. J.; Milligan, G. Allostery at G Protein-Coupled Receptor Homo-And Heteromers: Uncharted Pharmacological Landscapes. Pharmacol. Rev. 2010, 62, 701-725.
67. Hay, D. L.; Pioszak, A. A. Receptor Activity-Modifying Proteins (RAMPs): New Insights and Roles. Annu. Rev. Pharmacol. Toxicol. 2016, 56, 469-487.
68. Lutz, M.; Kenakin, T. Quantitative Molecular Pharmacology and Informatics in Drug Discovery; John Wiley & Sons, Ltd.: New York, 1999.
69. May, L. T.; Leach, K.; Sexton, P. M.; Christopoulos, A. Allosteric Modulation of G Protein-Coupled Receptors. Annu. Rev. Pharmacol. Toxicol. 2007, 47, 1-51.
70. Ehlert, F. J. Functional Studies Cast Light on Receptor States. Trends Pharmacol. Sci. 2015, 36, 596-604.
71. Kenakin, T. P. '7TM Receptor Allostery: Putting Numbers to Shapeshifting Proteins. Trends Pharmacol. Sci. 2009, 30, 460-469.
72. Conn, P. J.; Lindsley, C. W.; Meiler, J.; Niswender, C. M. Opportunities and Challenges in the Discovery of Allosteric Modulators of GPCRs for Treating CNS Disorders. Nat. Rev. Drug Discovery 2014, 13, 692-708.
73. Melancon, B. J.; Hopkins, C. R.; Wood, M. R.; Emmitte, K. A.; Niswender, C. M.; Christopoulos, A.; Conn, P. J.; Lindsley, C. W. Allosteric Modulation of Seven Transmembrane Spanning Receptors: Theory, Practice, and Opportunities for Central Nervous System Drug Discovery. J. Med. Chem. 2012, 55, 1445-1464.
74. Muller, C. E.; Schiedel, A. C.; Baqi, Y. Allosteric Modulators of Rhodopsin-Like G Protein-Coupled Receptors: Opportunities in Drug Development. Pharmacol. Ther. 2012, 135, 292-315.
75. Kruse, A. C.; Kobilka, B. K.; Gautam, D.; Sexton, P. M.; Christopoulos, A.; Wess, J. Muscarinic Acetylcholine Receptors: Novel Opportunities for Drug Development. Nat. Rev. Drug Discovery 2014, 13, 549-560.
76. Gherbi, K.; May, L. T.; Baker, J. G.; Briddon, S. J.; Hill, S. J. Negative Cooperativity across β1-Adrenoceptor Homodimers Provides Insights into the Nature of the Secondary Low-Affinity CGP 12177 β1-Adrenoceptor Binding Conformation. FASEB J. 2015, 29, 2859-2871.
77. Lane, J. R.; Donthamsetti, P.; Shonberg, J.; Draper-Joyce, C. J.; Dentry, S.; Michino, M.; Shi, L.; Lopez, L.; Scammells, P. J.; Capuano, B.; et al. A New Mechanism of Allostery in a G Protein-Coupled Receptor Dimer. Nat. Chem. Biol. 2014, 10, 745-752.
78. Kobilka, B. K.; Deupi, X. Conformational Complexity of GProtein-Coupled Receptors. Trends Pharmacol. Sci. 2007, 28, 397-406.
79. Milligan, G.; Ijzerman, A. P. Stochastic Multidimensional Hypercubes and Inverse Agonism. Trends Pharmacol. Sci. 2000, 21, 362-363.
80. Onaran, H. O.; Rajagopal, S.; Costa, T. What Is Biased Efficacy? Defining the Relationship between Intrinsic Efficacy and Free Energy Coupling. Trends Pharmacol. Sci. 2014, 35, 639-647.
81. Masuho, I.; Ostrovskaya, O.; Kramer, G. M.; Jones, C. D.; Xie, K.; Martemyanov, K. A. Distinct Profiles of Functional Discrimination among G Proteins Determine the Actions of G Protein-Coupled Receptors. Sci. Signaling 2015, 8, ra123.
82. Shukla, A. K.; Xiao, K.; Lefkowitz, R. J. Emerging Paradigms of β-Arrestin-Dependent Seven Transmembrane Receptor Signaling. Trends Biochem. Sci. 2011, 36, 457-469.
83. Rajagopal, S.; Rajagopal, K.; Lefkowitz, R. J. Teaching Old Receptors New Tricks: Biasing Seven-Transmembrane Receptors. Nat. Rev. Drug Discovery 2010, 9, 373-386.
84. Violin, J. D.; Lefkowitz, R. J. Beta-Arrestin-Biased Ligands at Seven-Transmembrane Receptors. Trends Pharmacol. Sci. 2007, 28, 416-422.
85. Luttrell, L. M.; Maudsley, S.; Bohn, L. M. Fulfilling the Promise of "Biased" G Protein-Coupled Receptor Agonism. Mol. Pharmacol. 2015, 88, 579-588.
86. Bond, R. A.; Ijzerman, A. P. Recent Developments in Constitutive Receptor Activity and Inverse Agonism, and Their Potential for GPCR Drug Discovery. Trends Pharmacol. Sci. 2006, 27, 92-96.
87. Tehan, B. G.; Bortolato, A.; Blaney, F. E.; Weir, M. P.; Mason, J. S. Unifying Family a GPCR Theories of Activation. Pharmacol. Ther. 2014, 143, 51-60.
88. Smit, M. J.; Vischer, H. F.; Bakker, R. A.; Jongejan, A.; Timmerman, H.; Pardo, L.; Leurs, R. Pharmacogenomic and Structural Analysis of Constitutive G Protein-Coupled Receptor Activity. Annu. Rev. Pharmacol. Toxicol. 2007, 47, 53-87.
89. Milligan, G. Constitutive Activity and Inverse Agonists of G Protein-Coupled Receptors: A Current Perspective. Mol. Pharmacol. 2003, 64, 1271-1276.
90. Milligan, G.; Bond, R. A.; Lee, M. Inverse Agonism: Pharmacological Curiosity or Potential Therapeutic Strategy? Trends Pharmacol. Sci. 1995, 16, 10-13.
91. Wise, A.; Jupe, S. C.; Rees, S. The Identification of Ligands at Orphan G-Protein Coupled Receptors. Annu. Rev. Pharmacol. Toxicol. 2004, 44, 43-66.
92. Civelli, O.; Reinscheid, R. K.; Zhang, Y.; Wang, Z.; Fredriksson, R.; Schioth, H. B. G Protein-Coupled Receptor Deorphanizations. Annu. Rev. Pharmacol. Toxicol. 2013, 53, 127-146.
93. Zhu, Y.; Michalovich, D.; Wu, H.; Tan, K. B.; Dytko, G. M.; Mannan, I. J.; Boyce, R.; Alston, J.; Tierney, L. A.; Li, X.; et al. Cloning, Expression, and Pharmacological Characterization of a Novel Human Histamine Receptor. Mol. Pharmacol. 2001, 59, 434-441.
94. Green, A.; Milligan, G.; Belt, S. E. Effects of Prolonged Treatment of Adipocytes with PGE1, N6-Phenylisopropyl Adenosine and Nicotinic Acid on G-Proteins and Antilipolytic Sensitivity. Biochem. Soc. Trans. 1991, 19, 212S.
95. Offermanns, S.; Colletti, S. L.; Lovenberg, T. W.; Semple, G.; Wise, A.; IJzerman, A. P. International Union of Basic and Clinical Pharmacology. LXXXII: Nomenclature and Classification of Hydroxy-Carboxylic Acid Receptors (GPR81, GPR109a, and GPR109b). Pharmacol. Rev. 2011, 63, 269-290.
96. Liu, C.; Wu, J.; Zhu, J.; Kuei, C.; Yu, J.; Shelton, J.; Sutton, S. W.; Li, X.; Yun, S. J.; Mirzadegan, T.; et al. Lactate Inhibits Lipolysis in Fat Cells through Activation of an Orphan G-Protein-Coupled Receptor, GPR81. J. Biol. Chem. 2009, 284, 2811-2822.
97. Meder, W.; Wendland, M.; Busmann, A.; Kutzleb, C.; Spodsberg, N.; John, H.; Richter, R.; Schleuder, D.; Meyer, M.; Forssmann, W. G. Characterization of Human Circulating Tig2 as a Ligand for the Orphan Receptor Chemr23. FEBS Lett. 2003, 555, 495-499.
98. Wittamer, V.; Franssen, J. D.; Vulcano, M.; Mirjolet, J. F.; Le Poul, E.; Migeotte, I.; Brezillon, S.; Tyldesley, R.; Blanpain, C.; Detheux, M.; et al. Specific Recruitment of Antigen-Presenting Cells by Chemerin, a Novel Processed Ligand from Human Inflammatory Fluids. J. Exp. Med. 2003, 198, 977-985.
99. Stoddart, L. A.; Smith, N. J.; Milligan, G. International Union of Pharmacology. LXXI. Free Fatty Acid Receptors FFA1,-2, and-3: Pharmacology and Pathophysiological Functions. Pharmacol. Rev. 2008, 60, 405-417.
100. Davenport, A. P.; Alexander, S. P.; Sharman, J. L.; Pawson, A. J.; Benson, H. E.; Monaghan, A. E.; Liew, W. C.; Mpamhanga, C. P.; Bonner, T. I.; Neubig, R. R.; et al. International Union of Basic and Clinical Pharmacology. LXXXVIII. G Protein-Coupled Receptor List: Recommendations for New Pairings with Cognate Ligands. Pharmacol. Rev. 2013, 65, 967-986.
101. Sawzdargo, M.; George, S. R.; Nguyen, T.; Xu, S.; Kolakowski, L. F.; O'Dowd, B. F. A Cluster of Four Novel Human G Protein-Coupled Receptor Genes Occurring in Close Proximity to CD22 Gene on Chromosome 19q13.1. Biochem. Biophys. Res. Commun. 1997, 239, 543-547.
102. Briscoe, C. P.; Tadayyon, M.; Andrews, J. L.; Benson, W. G.; Chambers, J. K.; Eilert, M. M.; Ellis, C.; Elshourbagy, N. A.; Goetz, A. S.; Minnick, D. T.; et al. The Orphan G Protein-Coupled Receptor GPR40 Is Activated by Medium and Long Chain Fatty Acids. J. Biol. Chem. 2003, 278, 11303-11311.
103. Itoh, Y.; Kawamata, Y.; Harada, M.; Kobayashi, M.; Fujii, R.; Fukusumi, S.; Ogi, K.; Hosoya, M.; Tanaka, Y.; Uejima, H.; et al. Free Fatty Acids Regulate Insulin Secretion from Pancreatic Beta Cells through GPR40. Nature 2003, 422, 173-176.
104. Kotarsky, K.; Nilsson, N. E.; Flodgren, E.; Owman, C.; Olde, B. A Human Cell Surface Receptor Activated by Free Fatty Acids and Thiazolidinedione Drugs. Biochem. Biophys. Res. Commun. 2003, 301, 406-410.
105. Takasaki, J.; Saito, T.; Taniguchi, M.; Kawasaki, T.; Moritani, Y.; Hayashi, K.; Kobori, M. A Novel Galphaq/11-Selective Inhibitor. J. Biol. Chem. 2004, 279, 47438-47445.
106. Fujiwara, K.; Maekawa, F.; Yada, T. Oleic Acid Interacts with GPR40 to Induce Ca2+ Signaling in Rat Islet Beta-Cells: Mediation by PLC and L-Type Ca2+ Channel and Link to Insulin Release. Am. J. Physiol. Endocrinol. Metab. 2005, 289, E670-E677.
107. Shapiro, H.; Shachar, S.; Sekler, I.; Hershfinkel, M.; Walker, M. D. Role of GPR40 in Fatty Acid Action on the Beta Cell Line INS-1E. Biochem. Biophys. Res. Commun. 2005, 335, 97-104.
108. Stoddart, L. A.; Brown, A. J.; Milligan, G. Uncovering the Pharmacology of the G Protein-Coupled Receptor GPR40: High Apparent Constitutive Activity in Guanosine 5′-O-(3-[35S]Thio)-Triphosphate Binding Studies Reflects Binding of an Endogenous Agonist. Mol. Pharmacol. 2007, 71, 994-1005.
109. Latour, M. G.; Alquier, T.; Oseid, E.; Tremblay, C.; Jetton, T. L.; Luo, J.; Lin, D. C.; Poitout, V. GPR40 Is Necessary but Not Sufficient for Fatty Acid Stimulation of Insulin Secretion in Vivo. Diabetes 2007, 56, 1087-1094.
110. Schrage, R.; Schmitz, A. L.; Gaffal, E.; Annala, S.; Kehraus, S.; Wenzel, D.; Bullesbach, K. M.; Bald, T.; Inoue, A.; Shinjo, Y.; et al. The Experimental Power of FR900359 to Study Gq-Regulated Biological Processes. Nat. Commun. 2015, 6, 10156.
111. Hardy, S.; St-Onge, G. G.; Joly, E.; Langelier, Y.; Prentki, M. Oleate Promotes the Proliferation of Breast Cancer Cells Via the G Protein-Coupled Receptor GPR40. J. Biol. Chem. 2005, 280, 13285-13291.
112. Yonezawa, T.; Katoh, K.; Obara, Y. Existence of GPR40 Functioning in a Human Breast Cancer Cell Line, MCF-7. Biochem. Biophys. Res. Commun. 2004, 314, 805-809.
113. Fujita, T.; Matsuoka, T.; Honda, T.; Kabashima, K.; Hirata, T.; Narumiya, S. A GPR40 Agonist Gw9508 Suppresses CCL5, CCL17, and CXCL10 Induction in Keratinocytes and Attenuates Cutaneous Immune Inflammation. J. Invest. Dermatol. 2011, 131, 1660-1667.
114. Feng, D. D.; Luo, Z.; Roh, S. G.; Hernandez, M.; Tawadros, N.; Keating, D. J.; Chen, C. Reduction in Voltage-Gated K+ Currents in Primary Cultured Rat Pancreatic Beta-Cells by Linoleic Acids. Endocrinology 2006, 147, 674-682.
115. Hauge, M.; Vestmar, M. A.; Husted, A. S.; Ekberg, J. P.; Wright, M. J.; Di Salvo, J.; Weinglass, A. B.; Engelstoft, M. S.; Madsen, A. N.; Luckmann, M.; et al. GPR40 (FFAR1)-Combined Gs and Gq Signaling in Vitro Is Associated with Robust Incretin Secretagogue Action Ex Vivo and in Vivo. Mol. Metab. 2015, 4, 3-14.
116. Mancini, A. D.; Bertrand, G.; Vivot, K.; Carpentier, E.; Tremblay, C.; Ghislain, J.; Bouvier, M.; Poitout, V. β-Arrestin Recruitment and Biased Agonism at Free Fatty Acid Receptor 1. J. Biol. Chem. 2015, 290, 21131-21140.
117. Qian, J.; Wu, C.; Chen, X.; Li, X.; Ying, G.; Jin, L.; Ma, Q.; Li, G.; Shi, Y.; Zhang, G.; et al. Differential Requirements of Arrestin-3 and Clathrin for Ligand-Dependent and-Independent Internalization of Human G Protein-Coupled Receptor 40. Cell. Signalling 2014, 26, 2412-2423.
118. Shimpukade, B.; Hudson, B. D.; Hovgaard, C. K.; Milligan, G.; Ulven, T. Discovery of a Potent and Selective GPR120 Agonist. J. Med. Chem. 2012, 55, 4511-4515.
119. Tomita, T.; Masuzaki, H.; Iwakura, H.; Fujikura, J.; Noguchi, M.; Tanaka, T.; Ebihara, K.; Kawamura, J.; Komoto, I.; Kawaguchi, Y.; et al. Expression of the Gene for a Membrane-Bound Fatty Acid Receptor in the Pancreas and Islet Cell Tumours in Humans: Evidence for GPR40 Expression in Pancreatic Beta Cells and Implications for Insulin Secretion. Diabetologia 2006, 49, 962-968.
120. Flodgren, E.; Olde, B.; Meidute-Abaraviciene, S.; Winzell, M. S.; Ahren, B.; Salehi, A. GPR40 Is Expressed in Glucagon Producing Cells and Affects Glucagon Secretion. Biochem. Biophys. Res. Commun. 2007, 354, 240-245.
121. Lan, H.; Hoos, L. M.; Liu, L.; Tetzloff, G.; Hu, W.; Abbondanzo, S. J.; Vassileva, G.; Gustafson, E. L.; Hedrick, J. A.; Davis, H. R. Lack of FFAR1/GPR40 Does Not Protect Mice from High-Fat Diet-Induced Metabolic Disease. Diabetes 2008, 57, 2999-3006.
122. Wang, L.; Zhao, Y.; Gui, B.; Fu, R.; Ma, F.; Yu, J.; Qu, P.; Dong, L.; Chen, C. Acute Stimulation of Glucagon Secretion by Linoleic Acid Results from GPR40 Activation and [Ca2+]I Increase in Pancreatic Islet α-Cells. J. Endocrinol. 2011, 210, 173-179.
123. Edfalk, S.; Steneberg, P.; Edlund, H. GPR40 Is Expressed in Enteroendocrine Cells and Mediates Free Fatty Acid Stimulation of Incretin Secretion. Diabetes 2008, 57, 2280-2287.
124. Liou, A. P.; Lu, X.; Sei, Y.; Zhao, X.; Pechhold, S.; Carrero, R. J.; Raybould, H. E.; Wank, S. The G-Protein-Coupled Receptor GPR40 Directly Mediates Long-Chain Fatty Acid-Induced Secretion of Cholecystokinin. Gastroenterology 2011, 140, 903-912.
125. Sykaras, A. G.; Demenis, C.; Case, R. M.; McLaughlin, J. T.; Smith, C. P. Duodenal Enteroendocrine I-Cells Contain mRNA Transcripts Encoding Key Endocannabinoid and Fatty Acid Receptors. PLoS One 2012, 7, e42373.
126. Parker, H. E.; Habib, A. M.; Rogers, G. J.; Gribble, F. M.; Reimann, F. Nutrient-Dependent Secretion of Glucose-Dependent Insulinotropic Polypeptide from Primary Murine K Cells. Diabetologia 2009, 52, 289-298.
127. Cornish, J.; MacGibbon, A.; Lin, J. M.; Watson, M.; Callon, K. E.; Tong, P. C.; Dunford, J. E.; van der Does, Y.; Williams, G. A.; Grey, A. B.; et al. Modulation of Osteoclastogenesis by Fatty Acids. Endocrinology 2008, 149, 5688-5695.
128. Khan, M. Z.; He, L. The Role of Polyunsaturated Fatty Acids and GPR40 Receptor in Brain. Neuropharmacology 2015.10.1016/j.neuropharm.2015.05.013
129. Christiansen, E.; Watterson, K. R.; Stocker, C. J.; Sokol, E.; Jenkins, L.; Simon, K.; Grundmann, M.; Petersen, R. K.; Wargent, E. T.; Hudson, B. D.; et al. Activity of Dietary Fatty Acids on FFA1 and FFA4 and Characterisation of Pinolenic Acid as a Dual FFA1/FFA4 Agonist with Potential Effect against Metabolic Diseases. Br. J. Nutr. 2015, 113, 1677.
130. Briscoe, C. P.; Peat, A. J.; McKeown, S. C.; Corbett, D. F.; Goetz, A. S.; Littleton, T. R.; McCoy, D. C.; Kenakin, T. P.; Andrews, J. L.; Ammala, C.; et al. Pharmacological Regulation of Insulin Secretion in Min6 Cells through the Fatty Acid Receptor GPR40: Identification of Agonist and Antagonist Small Molecules. Br. J. Pharmacol. 2006, 148, 619-628.
131. Kebede, M.; Alquier, T.; Latour, M. G.; Semache, M.; Tremblay, C.; Poitout, V. The Fatty Acid Receptor GPR40 Plays a Role in Insulin Secretion in Vivo after High-Fat Feeding. Diabetes 2008, 57, 3166-3166.
132. Salehi, A.; Flodgren, E.; Nilsson, N. E.; Jimenez-Feltstrom, J.; Miyazaki, J.; Owman, C.; Olde, B. Free Fatty Acid Receptor 1 (FFA(1)R/GPR40) and Its Involvement in Fatty-Acid-Stimulated Insulin Secretion. Cell Tissue Res. 2005, 322, 207-215.
133. Schnell, S.; Schaefer, M.; Schofl, C. Free Fatty Acids Increase Cytosolic Free Calcium and Stimulate Insulin Secretion from Beta-Cells through Activation of GPR40. Mol. Cell. Endocrinol. 2007, 263, 173-180.
134. Ferdaoussi, M.; Bergeron, V.; Zarrouki, B.; Kolic, J.; Cantley, J.; Fielitz, J.; Olson, E. N.; Prentki, M.; Biden, T.; MacDonald, P. E.; et al. G Protein-Coupled Receptor (GPR)40-Dependent Potentiation of Insulin Secretion in Mouse Islets Is Mediated by Protein Kinase D1. Diabetologia 2012, 55, 2682-2692.
135. Alquier, T.; Poitout, V. GPR40: Good Cop, Bad Cop? Diabetes 2009, 58, 1035-1036.
136. Hudson, B. D.; Smith, N. J.; Milligan, G. Experimental Challenges to Targeting Poorly Characterized GPCRs: Uncovering the Therapeutic Potential for Free Fatty Acid Receptors. Adv. Pharmacol. 2011, 62, 175-218.
137. Steneberg, P.; Rubins, N.; Bartoov-Shifman, R.; Walker, M. D.; Edlund, H. The FFA Receptor GPR40 Links Hyperinsulinemia, Hepatic Steatosis, and Impaired Glucose Homeostasis in Mouse. Cell Metab. 2005, 1, 245-258.
138. Panse, M.; Gerst, F.; Kaiser, G.; Teutsch, C. A.; Dolker, R.; Wagner, R.; Haring, H. U.; Ullrich, S. Activation of Extracellular Signal-Regulated Protein Kinases 1 and 2 (ERK1/2) by Free Fatty Acid Receptor 1 (FFAR1/GPR40) Protects from Palmitate-Induced Beta Cell Death, but Plays No Role in Insulin Secretion. Cell. Physiol. Biochem. 2015, 35, 1537-1545.
139. Wagner, R.; Kaiser, G.; Gerst, F.; Christiansen, E.; Due-Hansen, M. E.; Grundmann, M.; Machicao, F.; Peter, A.; Kostenis, E.; Ulven, T.; et al. Reevaluation of Fatty Acid Receptor 1 as a Drug Target for the Stimulation of Insulin Secretion in Humans. Diabetes 2013, 62, 2106-2111.
140. Kristinsson, H.; Smith, D. M.; Bergsten, P.; Sargsyan, E. FFAR1 Is Involved in Both the Acute and Chronic Effects of Palmitate on Insulin Secretion. Endocrinology 2013, 154, 4078-4088.
141. Natalicchio, A.; Labarbuta, R.; Tortosa, F.; Biondi, G.; Marrano, N.; Peschechera, A.; Carchia, E.; Orlando, M. R.; Leonardini, A.; Cignarelli, A.; et al. Exendin-4 Protects Pancreatic Beta Cells from Palmitate-Induced Apoptosis by Interfering with GPR40 and the MKK4/7 Stress Kinase Signalling Pathway. Diabetologia 2013, 56, 2456-2466.
142. Wu, J.; Sun, P.; Zhang, X.; Liu, H.; Jiang, H.; Zhu, W.; Wang, H. Inhibition of GPR40 Protects Min6 Beta Cells from Palmitate-Induced Er Stress and Apoptosis. J. Cell. Biochem. 2012, 113, 1152-1158.
143. Corbisier, J.; Gales, C.; Huszagh, A.; Parmentier, M.; Springael, J. Y. Biased Signaling at Chemokine Receptors. J. Biol. Chem. 2015, 290, 9542-9554.
144. Zweemer, A. J.; Toraskar, J.; Heitman, L. H.; IJzerman, A. P. Bias in Chemokine Receptor Signalling. Trends Immunol. 2014, 35, 243-252.
145. Yamashima, T. Dual Effects of the Non-Esterified Fatty Acid Receptor 'GPR40' for Human Health. Prog. Lipid Res. 2015, 58, 40-50.
146. Christensen, L. W.; Kuhre, R. E.; Janus, C.; Svendsen, B.; Holst, J. J. Vascular, but Not Luminal, Activation of FFAR1 (GPR40) Stimulates GLP-1 Secretion from Isolated Perfused Rat Small Intestine. Physiol. Rep. 2015, 3, e12551.
147. Stoddart, L. A.; Milligan, G. Constitutive Activity of GPR40/FFA1 Intrinsic or Assay Dependent? Methods Enzymol. 2010, 484, 569-590.
148. Sum, C. S.; Tikhonova, I. G.; Costanzi, S.; Gershengorn, M. C. Two Arginine-Glutamate Ionic Locks near the Extracellular Surface of FFAR1 Gate Receptor Activation. J. Biol. Chem. 2009, 284, 3529-3536.
149. Morgan, N. G.; Dhayal, S. G-Protein Coupled Receptors Mediating Long Chain Fatty Acid Signalling in the Pancreatic Beta-Cell. Biochem. Pharmacol. 2009, 78, 1419-1427.
150. Mancini, A. D.; Poitout, V. The Fatty Acid Receptor FFA1/GPR40 a Decade Later: How Much Do We Know? Trends Endocrinol. Metab. 2013, 24, 398-407.
151. Huang, H.; Dai, M. H.; Tao, Y. X. Physiology and Therapeutics of the Free Fatty Acid Receptor GPR40. Prog. Mol. Biol. Transl. Sci. 2014, 121, 67-94.
152. Brownlie, R.; Mayers, R. M.; Pierce, J. A.; Marley, A. E.; Smith, D. M. The Long-Chain Fatty Acid Receptor, GPR40, and Glucolipotoxicity: Investigations Using GPR40-Knockout Mice. Biochem. Soc. Trans. 2008, 36, 950-954.
153. Garrido, D. M.; Corbett, D. F.; Dwornik, K. A.; Goetz, A. S.; Littleton, T. R.; McKeown, S. C.; Mills, W. Y.; Smalley, T. L., Jr.; Briscoe, C. P.; Peat, A. J. Synthesis and Activity of Small Molecule GPR40 Agonists. Bioorg. Med. Chem. Lett. 2006, 16, 1840-1845.
154. Smith, N. J.; Stoddart, L. A.; Devine, N. M.; Jenkins, L.; Milligan, G. The Action and Mode of Binding of Thiazolidinedione Ligands at Free Fatty Acid Receptor 1. J. Biol. Chem. 2009, 284, 17527-17539.
155. Gras, D.; Chanez, P.; Urbach, V.; Vachier, I.; Godard, P.; Bonnans, C. Thiazolidinediones Induce Proliferation of Human Bronchial Epithelial Cells through the GPR40 Receptor. Am. J. Physiol. Lung Cell Mol. Physiol. 2009, 296, L970-978.
156. Mieczkowska, A.; Basle, M. F.; Chappard, D.; Mabilleau, G. Thiazolidinediones Induce Osteocyte Apoptosis by a G Protein-Coupled Receptor 40-Dependent Mechanism. J. Biol. Chem. 2012, 287, 23517-23526.
157. Tang, X. L.; Wang, C. N.; Zhu, X. Y.; Ni, X. Rosiglitazone Inhibition of Calvaria-Derived Osteoblast Differentiation is through Both of PPARγ and GPR40 and GSK3β-Dependent Pathway. Mol. Cell. Endocrinol. 2015, 413, 78-89.
158. Kim, H. S.; Hwang, Y. C.; Koo, S. H.; Park, K. S.; Lee, M. S.; Kim, K. W.; Lee, M. K. PPAR-γ Activation Increases Insulin Secretion through the up-Regulation of the Free Fatty Acid Receptor GPR40 in Pancreatic Beta-Cells. PLoS One 2013, 8, e50128.
159. Shen, X.; Yang, L.; Yan, S.; Wei, W.; Liang, L.; Zheng, H.; Cai, X. The Effect of FFAR1 on Pioglitazone-Mediated Attenuation of Palmitic Acid-Induced Oxidative Stress and Apoptosis in Betatc6 Cells. Metab., Clin. Exp. 2014, 63, 335-351.
160. Wang, S.; Awad, K. S.; Elinoff, J. M.; Dougherty, E. J.; Ferreyra, G. A.; Wang, J. Y.; Cai, R.; Sun, J.; Ptasinska, A.; Danner, R. L. G Protein-Coupled Receptor 40 (GPR40) and Peroxisome Proliferator-Activated Receptor Gamma (PPARγ): An Integrated Two-Receptor Signaling Pathway. J. Biol. Chem. 2015, 290, 19544-19557.
161. Tan, C. P.; Feng, Y.; Zhou, Y. P.; Eiermann, G. J.; Petrov, A.; Zhou, C.; Lin, S.; Salituro, G.; Meinke, P.; Mosley, R.; et al. Selective Small-Molecule Agonists of G Protein-Coupled Receptor 40 Promote Glucose-Dependent Insulin Secretion and Reduce Blood Glucose in Mice. Diabetes 2008, 57, 2211-2219.
162. Zhou, C.; Tang, C.; Chang, E.; Ge, M.; Lin, S.; Cline, E.; Tan, C. P.; Feng, Y.; Zhou, Y. P.; Eiermann, G. J.; et al. Discovery of 5-Aryloxy-2, 4-Thiazolidinediones as Potent GPR40 Agonists. Bioorg. Med. Chem. Lett. 2010, 20, 1298-1301.
163. Song, F.; Lu, S.; Gunnet, J.; Xu, J. Z.; Wines, P.; Proost, J.; Liang, Y.; Baumann, C.; Lenhard, J.; Murray, W. V.; et al. Synthesis and Biological Evaluation of 3-Aryl-3-(4-Phenoxy)-Propionic Acid as a Novel Series of G Protein-Coupled Receptor 40 Agonists. J. Med. Chem. 2007, 50, 2807-2817.
164. Bartoschek, S.; Klabunde, T.; Defossa, E.; Dietrich, V.; Stengelin, S.; Griesinger, C.; Carlomagno, T.; Focken, I.; Wendt, K. U. Drug Design for G-Protein-Coupled Receptors by a Ligand-Based Nmr Method. Angew. Chem., Int. Ed. 2010, 49, 1426-1429.
165. Christiansen, E.; Urban, C.; Merten, N.; Liebscher, K.; Karlsen, K. K.; Hamacher, A.; Spinrath, A.; Bond, A. D.; Drewke, C.; Ullrich, S.; et al. Discovery of Potent and Selective Agonists for the Free Fatty Acid Receptor 1 (FFA(1)/GPR40), a Potential Target for the Treatment of Type Ii Diabetes. J. Med. Chem. 2008, 51, 7061-7064.
166. Christiansen, E.; Hansen, S. V.; Urban, C.; Hudson, B. D.; Wargent, E. T.; Grundmann, M.; Jenkins, L.; Zaibi, M.; Stocker, C. J.; Ullrich, S.; et al. Discovery of TUG-770: A Highly Potent Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist for Treatment of Type 2 Diabetes. ACS Med. Chem. Lett. 2013, 4, 441-445.
167. Christiansen, E.; Due-Hansen, M. E.; Urban, C.; Grundmann, M.; Schmidt, J.; Hansen, S. V.; Hudson, B. D.; Zaibi, M.; Markussen, S. B.; Hagesaether, E.; et al. Discovery of a Potent and Selective Free Fatty Acid Receptor 1 Agonist with Low Lipophilicity and High Oral Bioavailability. J. Med. Chem. 2013, 56, 982-992.
168. Hagesaether, E.; Christiansen, E.; Due-Hansen, M. E.; Ulven, T. Mucus Can Change the Permeation Rank Order of Drug Candidates. Int. J. Pharm. 2013, 452, 276-282.
169. Christiansen, E.; Due-Hansen, M. E.; Urban, C.; Merten, N.; Pfleiderer, M.; Karlsen, K. K.; Rasmussen, S. S.; Steensgaard, M.; Hamacher, A.; Schmidt, J.; et al. Structure-Activity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469. ACS Med. Chem. Lett. 2010, 1, 345-349.
170. Christiansen, E.; Due-Hansen, M. E.; Urban, C.; Grundmann, M.; Schroder, R.; Hudson, B. D.; Milligan, G.; Cawthorne, M. A.; Kostenis, E.; Kassack, M. U.; et al. Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonists: Mesylpropoxy Appendage Lowers Lipophilicity and Improves Adme Properties. J. Med. Chem. 2012, 55, 6624-6628.
171. Negoro, N.; Sasaki, S.; Mikami, S.; Ito, M.; Suzuki, M.; Tsujihata, Y.; Ito, R.; Harada, A.; Takeuchi, K.; Suzuki, N.; et al. Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist. ACS Med. Chem. Lett. 2010, 1, 290-294.
172. Negoro, N.; Sasaki, S.; Mikami, S.; Ito, M.; Tsujihata, Y.; Ito, R.; Suzuki, M.; Takeuchi, K.; Suzuki, N.; Miyazaki, J.; et al. Optimization of (2, 3-Dihydro-1-Benzofuran-3-Yl)Acetic Acids: Discovery of a Non-Free Fatty Acid-Like, Highly Bioavailable G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1 Agonist as a Glucose-Dependent Insulinotropic Agent. J. Med. Chem. 2012, 55, 3960-3974.
173. Sasaki, S.; Kitamura, S.; Negoro, N.; Suzuki, M.; Tsujihata, Y.; Suzuki, N.; Santou, T.; Kanzaki, N.; Harada, M.; Tanaka, Y.; et al. Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists. J. Med. Chem. 2011, 54, 1365-1378.
174. Tanaka, H.; Yoshida, S.; Minoura, H.; Negoro, K.; Shimaya, A.; Shimokawa, T.; Shibasaki, M. Novel GPR40 Agonist AS2575959 Exhibits Glucose Metabolism Improvement and Synergistic Effect with Sitagliptin on Insulin and Incretin Secretion. Life Sci. 2014, 94, 115-121.
175. Defossa, E.; Wagner, M. Recent Developments in the Discovery of FFA1 Receptor Agonists as Novel Oral Treatment for Type 2 Diabetes Mellitus. Bioorg. Med. Chem. Lett. 2014, 24, 2991-3000.
176. Lu, H.; Fei, H.; Yang, F.; Zheng, S.; Hu, Q.; Zhang, L.; Yuan, J.; Feng, J.; Sun, P.; Dong, Q. Discovery of Novel Orally Bioavailable GPR40 Agonists. Bioorg. Med. Chem. Lett. 2013, 23, 2920-2924.
177. Takano, R.; Yoshida, M.; Inoue, M.; Honda, T.; Nakashima, R.; Matsumoto, K.; Yano, T.; Ogata, T.; Watanabe, N.; Hirouchi, M.; et al. Discovery of DS-1558: A Potent and Orally Bioavailable GPR40 Agonist. ACS Med. Chem. Lett. 2015, 6, 266-270.
178. Takeuchi, M.; Hirasawa, A.; Hara, T.; Kimura, I.; Hirano, T.; Suzuki, T.; Miyata, N.; Awaji, T.; Ishiguro, M.; Tsujimoto, G. FFA1-Selective Agonistic Activity Based on Docking Simulation Using FFA1 and GPR120 Homology Models. Br. J. Pharmacol. 2013, 168, 1570-1583.
179. Zahanich, I.; Kondratov, I.; Naumchyk, V.; Kheylik, Y.; Platonov, M.; Zozulya, S.; Krasavin, M. Phenoxymethyl 1, 3-Oxazoles and 1, 2, 4-Oxadiazoles as Potent and Selective Agonists of Free Fatty Acid Receptor 1 (GPR40). Bioorg. Med. Chem. Lett. 2015, 25, 3105-3111.
180. Tsujihata, Y.; Ito, R.; Suzuki, M.; Harada, A.; Negoro, N.; Yasuma, T.; Momose, Y.; Takeuchi, K. TAK-875, an Orally Available G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1 Agonist, Enhances Glucose-Dependent Insulin Secretion and Improves Both Postprandial and Fasting Hyperglycemia in Type 2 Diabetic Rats. J. Pharmacol. Exp. Ther. 2011, 339, 228-237.
181. Yashiro, H.; Tsujihata, Y.; Takeuchi, K.; Hazama, M.; Johnson, P. R.; Rorsman, P. The Effects of TAK-875, a Selective G Protein-Coupled Receptor 40/Free Fatty Acid 1 Agonist, on Insulin and Glucagon Secretion in Isolated Rat and Human Islets. J. Pharmacol. Exp. Ther. 2012, 340, 483-489.
182. Luo, J.; Swaminath, G.; Brown, S. P.; Zhang, J.; Guo, Q.; Chen, M.; Nguyen, K.; Tran, T.; Miao, L.; Dransfield, P. J.; et al. A Potent Class of GPR40 Full Agonists Engages the Enteroinsular Axis to Promote Glucose Control in Rodents. PLoS One 2012, 7, e46300.
183. Leifke, E.; Naik, H.; Wu, J.; Viswanathan, P.; Demanno, D.; Kipnes, M.; Vakilynejad, M. A Multiple-Ascending-Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Novel GPR40 Agonist, TAK-875, in Subjects with Type 2 Diabetes. Clin. Pharmacol. Ther. 2012, 92, 29-39.
184. Naik, H.; Vakilynejad, M.; Wu, J.; Viswanathan, P.; Dote, N.; Higuchi, T.; Leifke, E. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of the GPR40 Agonist TAK-875: Results from a Double-Blind, Placebo-Controlled Single Oral Dose Rising Study in Healthy Volunteers. J. Clin. Pharmacol. 2012, 52, 1007-1016.
185. Kaku, K.; Enya, K.; Nakaya, R.; Ohira, T.; Matsuno, R. Efficacy and Safety of Fasiglifam (TAK-875), a G Protein-Coupled Receptor 40 Agonist, in Japanese Patients with Type 2 Diabetes Inadequately Controlled by Diet and Exercise: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial. Diabetes, Obes. Metab. 2015, 17, 675-681.
186. Mancini, A. D.; Poitout, V. GPR40 Agonists for the Treatment of Type 2 Diabetes: Life after 'Taking' a Hit. Diabetes, Obes. Metab. 2015, 17, 622-629.
187. Burant, C. F.; Viswanathan, P.; Marcinak, J.; Cao, C.; Vakilynejad, M.; Xie, B.; Leifke, E. TAK-875 Versus Placebo or Glimepiride in Type 2 Diabetes Mellitus: A Phase 2, Randomised, Double-Blind, Placebo-Controlled Trial. Lancet 2012, 379, 1403-1411.
188. Araki, T.; Hirayama, M.; Hiroi, S.; Kaku, K. GPR40-Induced Insulin Secretion by the Novel Agonist TAK-875: First Clinical Findings in Patients with Type 2 Diabetes. Diabetes, Obes. Metab. 2012, 14, 271-278.
189. Li, X.; Zhong, K.; Guo, Z.; Zhong, D.; Chen, X. Fasiglifam (TAK-875) Inhibits Hepatobiliary Transporters: A Possible Factor Contributing to Fasiglifam-Induced Liver Injury. Drug Metab. Dispos. 2015, 43, 1751-1759.
190. Sum, C. S.; Tikhonova, I. G.; Neumann, S.; Engel, S.; Raaka, B. M.; Costanzi, S.; Gershengorn, M. C. Identification of Residues Important for Agonist Recognition and Activation in GPR40. J. Biol. Chem. 2007, 282, 29248-29255.
191. Tikhonova, I. G.; Sum, C. S.; Neumann, S.; Thomas, C. J.; Raaka, B. M.; Costanzi, S.; Gershengorn, M. C. Bidirectional, Iterative Approach to the Structural Delineation of the Functional "Chemoprint" in GPR40 for Agonist Recognition. J. Med. Chem. 2007, 50, 2981-2989.
192. Ballesteros, J. A.; Weinstein, H. Methods in Neuroscience; Elsevier: New York, 1995; Vol. 25, pp 366-428.
193. Halder, S.; Kumar, S.; Sharma, R. The Therapeutic Potential of GPR120: A Patent Review. Expert Opin. Ther. Pat. 2013, 23, 1581-1590.
194. Srivastava, A.; Yano, J.; Hirozane, Y.; Kefala, G.; Gruswitz, F.; Snell, G.; Lane, W.; Ivetac, A.; Aertgeerts, K.; Nguyen, J.; et al. High-Resolution Structure of the Human GPR40 Receptor Bound to Allosteric Agonist TAK-875. Nature 2014, 513, 124-127.
195. Hanson, M. A.; Roth, C. B.; Jo, E. J.; Griffith, M. T.; Scott, F. L.; Reinhart, G.; Desale, H.; Clemons, B.; Cahalan, S. M.; Schuerer, S. C.; et al. Crystal Structure of a Lipid G Protein-Coupled Receptor. Science 2012, 335, 851-855.
196. Tikhonova, I. G.; Poerio, E. Free Fatty Acid Receptors: Structural Models and Elucidation of Ligand Binding Interactions. BMC Struct. Biol. 2015, 15, 16.
197. Lin, D. C.; Guo, Q.; Luo, J.; Zhang, J.; Nguyen, K.; Chen, M.; Tran, T.; Dransfield, P. J.; Brown, S. P.; Houze, J.; et al. Identification and Pharmacological Characterization of Multiple Allosteric Binding Sites on the Free Fatty Acid 1 Receptor. Mol. Pharmacol. 2012, 82, 843-859.
198. Houze, J. B.; Zhu, L.; Sun, Y.; Akerman, M.; Qiu, W.; Zhang, A. J.; Sharma, R.; Schmitt, M.; Wang, Y.; Liu, J.; et al. AMG 837: A Potent, Orally Bioavailable GPR40 Agonist. Bioorg. Med. Chem. Lett. 2012, 22, 1267-1270.
199. Yabuki, C.; Komatsu, H.; Tsujihata, Y.; Maeda, R.; Ito, R.; Matsuda-Nagasumi, K.; Sakuma, K.; Miyawaki, K.; Kikuchi, N.; Takeuchi, K.; et al. A Novel Antidiabetic Drug, Fasiglifam/TAK-875, Acts as an Ago-Allosteric Modulator of FFAR1. PLoS One 2013, 8, e76280.
200. Xiong, Y.; Swaminath, G.; Cao, Q.; Yang, L.; Guo, Q.; Salomonis, H.; Lu, J.; Houze, J. B.; Dransfield, P. J.; Wang, Y.; et al. Activation of FFA1 Mediates GLP-1 Secretion in Mice. Evidence for Allosterism at FFA1. Mol. Cell. Endocrinol. 2013, 369, 119-129.
201. Brown, S. P.; Dransfield, P. J.; Vimolratana, M.; Jiao, X.; Zhu, L.; Pattaropong, V.; Sun, Y.; Liu, J.; Luo, J.; Zhang, J.; et al. Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist. ACS Med. Chem. Lett. 2012, 3, 726-730.
202. El-Azzouny, M.; Evans, C. R.; Treutelaar, M. K.; Kennedy, R. T.; Burant, C. F. Increased Glucose Metabolism and Glycerolipid Formation by Fatty Acids and GPR40 Receptor Signaling Underlies the Fatty Acid Potentiation of Insulin Secretion. J. Biol. Chem. 2014, 289, 13575-13588.
203. Hudson, B. D.; Shimpukade, B.; Mackenzie, A. E.; Butcher, A. J.; Pediani, J. D.; Christiansen, E.; Heathcote, H.; Tobin, A. B.; Ulven, T.; Milligan, G. The Pharmacology of TUG-891, a Potent and Selective Agonist of the Free Fatty Acid Receptor 4 (FFA4/GPR120), Demonstrates Both Potential Opportunity and Possible Challenges to Therapeutic Agonism. Mol. Pharmacol. 2013, 84, 710-725.
204. Tsukahara, T.; Watanabe, K.; Watanabe, T.; Yamagami, H.; Sogawa, M.; Tanigawa, T.; Shiba, M.; Tominaga, K.; Fujiwara, Y.; Maeda, K.; et al. Tumor Necrosis Factor Alpha Decreases Glucagon-Like Peptide-2 Expression by up-Regulating G-Protein-Coupled Receptor 120 in Crohn Disease. Am. J. Pathol. 2015, 185, 185-196.
205. Karki, P.; Kurihara, T.; Nakamachi, T.; Watanabe, J.; Asada, T.; Oyoshi, T.; Shioda, S.; Yoshimura, M.; Arita, K.; Miyata, A. Attenuation of Inflammatory and Neuropathic Pain Behaviors in Mice through Activation of Free Fatty Acid Receptor GPR40. Mol. Pain 2015, 11, 6.
206. Nakamoto, K.; Aizawa, F.; Nishinaka, T.; Tokuyama, S. Regulation of Prohormone Convertase 2 Protein Expression Via GPR40/FFA1 in the Hypothalamus. Eur. J. Pharmacol. 2015, 762, 459-463.
207. Nakamoto, K.; Nishinaka, T.; Sato, N.; Mankura, M.; Koyama, Y.; Kasuya, F.; Tokuyama, S. Hypothalamic GPR40 Signaling Activated by Free Long Chain Fatty Acids Suppresses CFA-Induced Inflammatory Chronic Pain. PLoS One 2013, 8, e81563.
208. Tikhonova, I. G.; Sum, C. S.; Neumann, S.; Engel, S.; Raaka, B. M.; Costanzi, S.; Gershengorn, M. C. Discovery of Novel Agonists and Antagonists of the Free Fatty Acid Receptor 1 (FFAR1) Using Virtual Screening. J. Med. Chem. 2008, 51, 625-633.
209. Hu, H.; He, L. Y.; Gong, Z.; Li, N.; Lu, Y. N.; Zhai, Q. W.; Liu, H.; Jiang, H. L.; Zhu, W. L.; Wang, H. Y. A Novel Class of Antagonists for the FFAs Receptor GPR40. Biochem. Biophys. Res. Commun. 2009, 390, 557-563.
210. Zhang, X.; Yan, G.; Li, Y.; Zhu, W.; Wang, H. DC260126, a Small-Molecule Antagonist of GPR40, Improves Insulin Tolerance but Not Glucose Tolerance in Obese Zucker Rats. Biomed. Pharmacother. 2010, 64, 647-651.
211. Sun, P.; Wang, T.; Zhou, Y.; Liu, H.; Jiang, H.; Zhu, W.; Wang, H. DC260126: A Small-Molecule Antagonist of GPR40 That Protects against Pancreatic Beta-Cells Dysfunction in Db/Db Mice. PLoS One 2013, 8, e66744.
212. Humphries, P. S.; Benbow, J. W.; Bonin, P. D.; Boyer, D.; Doran, S. D.; Frisbie, R. K.; Piotrowski, D. W.; Balan, G.; Bechle, B. M.; Conn, E. L.; et al. Synthesis and Sar of 1, 2, 3, 4-Tetrahydroisoquinolin-1-Ones as Novel G-Protein-Coupled Receptor 40 (GPR40) Antagonists. Bioorg. Med. Chem. Lett. 2009, 19, 2400-2403.
213. Schmidt, J.; Liebscher, K.; Merten, N.; Grundmann, M.; Mielenz, M.; Sauerwein, H.; Christiansen, E.; Due-Hansen, M. E.; Ulven, T.; Ullrich, S.; et al. Conjugated Linoleic Acids Mediate Insulin Release through Islet G Protein-Coupled Receptor FFA1/GPR40. J. Biol. Chem. 2011, 286, 11890-11894.
214. Waring, M. J.; Baker, D. J.; Bennett, S. N. L.; Dossetter, A. G.; Garcia, M. F. R.; Georgsson, J.; Groombridge, S. D.; Loxham, S.; MacFaul, P. A.; Maskill, K. G.; et al. Discovery of a Series of 2-(Pyridinyl)Pyrimidines as Potent Antagonists of GPR40. MedChem-Comm 2015, 6, 1024-1029.
215. Hudson, B. D.; Murdoch, H.; Milligan, G. Minireview: The Effects of Species Ortholog and SNP Variation on Receptors for Free Fatty Acids. Mol. Endocrinol. 2013, 27, 1177-1187.
216. Briddon, S. J.; Kellam, B.; Hill, S. J. Design and Use of Fluorescent Ligands to Study Ligand-Receptor Interactions in Single Living Cells. Methods Mol. Biol. 2011, 746, 211-236.
217. Hara, T.; Hirasawa, A.; Sun, Q.; Koshimizu, T. A.; Itsubo, C.; Sadakane, K.; Awaji, T.; Tsujimoto, G. Flow Cytometry-Based Binding Assay for GPR40 (FFAR1; Free Fatty Acid Receptor 1). Mol. Pharmacol. 2009, 75, 85-91.
218. Bertrand, R.; Wolf, A.; Ivashchenko, Y.; Lohn, M.; Schafer, M.; Bronstrup, M.; Gotthardt, M.; Derdau, V.; Plettenburg, O. Synthesis and Characterization of a Promising Novel FFAR1/GPR40 Targeting Fluorescent Probe for Beta-Cell Imaging. ACS Chem. Biol. 2016.
219. Ren, X. M.; Cao, L. Y.; Zhang, J.; Qin, W. P.; Yang, Y.; Wan, B.; Guo, L. H. Investigation of the Binding Interaction of Fatty Acids with Human G Protein-Coupled Receptor 40 Using a Site-Specific Fluorescence Probe by Flow Cytometry. Biochemistry 2016, 55, 1989-1996.
220. Christiansen, E.; Hudson, B. D.; Hansen, A. H.; Milligan, G.; Ulven, T. Development and Characterization of a Potent Free Fatty Acid Receptor 1 (FFA1) Fluorescent Tracer. J. Med. Chem. 2016, 59, 4849.
221. Stoddart, L. A.; Johnstone, E. K. M.; Wheal, A. J.; Goulding, J.; Robers, M. B.; Machleidt, T.; Wood, K. V.; Hill, S. J.; Pfleger, K. D. G. Application of Bret to Monitor Ligand Binding to GPCRs. Nat. Methods 2015, 12, 661-663.
222. Brown, A. J.; Goldsworthy, S. M.; Barnes, A. A.; Eilert, M. M.; Tcheang, L.; Daniels, D.; Muir, A. I.; Wigglesworth, M. J.; Kinghorn, I.; Fraser, N. J.; et al. The Orphan G Protein-Coupled Receptors GPR41 and GPR43 Are Activated by Propionate and Other Short Chain Carboxylic Acids. J. Biol. Chem. 2003, 278, 11312-11319.
223. Le Poul, E.; Loison, C.; Struyf, S.; Springael, J. Y.; Lannoy, V.; Decobecq, M. E.; Brezillon, S.; Dupriez, V.; Vassart, G.; Van Damme, J.; et al. Functional Characterization of Human Receptors for Short Chain Fatty Acids and Their Role in Polymorphonuclear Cell Activation. J. Biol. Chem. 2003, 278, 25481-25489.
224. Nilsson, N. E.; Kotarsky, K.; Owman, C.; Olde, B. Identification of a Free Fatty Acid Receptor, FFA2r, Expressed on Leukocytes and Activated by Short-Chain Fatty Acids. Biochem. Biophys. Res. Commun. 2003, 303, 1047-1052.
225. Stoddart, L. A.; Smith, N. J.; Jenkins, L.; Brown, A. J.; Milligan, G. Conserved Polar Residues in Transmembrane Domains V, VI, and VII of Free Fatty Acid Receptor 2 and Free Fatty Acid Receptor 3 Are Required for the Binding and Function of Short Chain Fatty Acids. J. Biol. Chem. 2008, 283, 32913-32924.
226. Hudson, B. D.; Christiansen, E.; Tikhonova, I. G.; Grundmann, M.; Kostenis, E.; Adams, D. R.; Ulven, T.; Milligan, G. Chemically Engineering Ligand Selectivity at the Free Fatty Acid Receptor 2 Based on Pharmacological Variation between Species Orthologs. FASEB J. 2012, 26, 4951-4965.
227. Hudson, B. D.; Due-Hansen, M. E.; Christiansen, E.; Hansen, A. M.; Mackenzie, A. E.; Murdoch, H.; Pandey, S. K.; Ward, R. J.; Marquez, R.; Tikhonova, I. G.; et al. Defining the Molecular Basis for the First Potent and Selective Orthosteric Agonists of the FFA2 Free Fatty Acid Receptor. J. Biol. Chem. 2013, 288, 17296-17312.
228. Lee, S. U.; In, H. J.; Kwon, M. S.; Park, B. O.; Jo, M.; Kim, M. O.; Cho, S.; Lee, S.; Lee, H. J.; Kwak, Y. S.; et al. β-Arrestin 2 Mediates G Protein-Coupled Receptor 43 Signals to Nuclear Factor-Kappab. Biol. Pharm. Bull. 2013, 36, 1754-1759.
229. Nohr, M. K.; Pedersen, M. H.; Gille, A.; Egerod, K. L.; Engelstoft, M. S.; Husted, A. S.; Sichlau, R. M.; Grunddal, K. V.; Poulsen, S. S.; Han, S.; et al. GPR41/FFAR3 and GPR43/FFAR2 as Cosensors for Short-Chain Fatty Acids in Enteroendocrine Cells Vs FFAR3 in Enteric Neurons and FFAR2 in Enteric Leukocytes. Endocrinology 2013, 154, 3552-3564.
230. Karaki, S.; Mitsui, R.; Hayashi, H.; Kato, I.; Sugiya, H.; Iwanaga, T.; Furness, J. B.; Kuwahara, A. Short-Chain Fatty Acid Receptor, GPR43, Is Expressed by Enteroendocrine Cells and Mucosal Mast Cells in Rat Intestine. Cell Tissue Res. 2006, 324, 353-360.
231. Karaki, S.; Tazoe, H.; Hayashi, H.; Kashiwabara, H.; Tooyama, K.; Suzuki, Y.; Kuwahara, A. Expression of the Short-Chain Fatty Acid Receptor, GPR43, in the Human Colon. J. Mol. Histol. 2008, 39, 135-142.
232. Tazoe, H.; Otomo, Y.; Kaji, I.; Tanaka, R.; Karaki, S. I.; Kuwahara, A. Roles of Short-Chain Fatty Acids Receptors, GPR41 and GPR43 on Colonic Functions. J. Physiol. Pharmacol. 2008, 59 (Suppl 2), 251-262.
233. Tazoe, H.; Otomo, Y.; Karaki, S.; Kato, I.; Fukami, Y.; Terasaki, M.; Kuwahara, A. Expression of Short-Chain Fatty Acid Receptor GPR41 in the Human Colon. Biomed. Res. 2009, 30, 149-156.
234. Tolhurst, G.; Heffron, H.; Lam, Y. S.; Parker, H. E.; Habib, A. M.; Diakogiannaki, E.; Cameron, J.; Grosse, J.; Reimann, F.; Gribble, F. M. Short-Chain Fatty Acids Stimulate Glucagon-Like Peptide-1 Secretion Via the G-Protein-Coupled Receptor FFAR2. Diabetes 2012, 61, 364-371.
235. Kebede, M. A.; Alquier, T.; Latour, M. G.; Poitout, V. Lipid Receptors and Islet Function: Therapeutic Implications? Diabetes, Obes. Metab. 2009, 11 (Suppl 4), 10-20.
236. McNelis, J. C.; Lee, Y. S.; Mayoral, R.; van der Kant, R.; Johnson, A. M.; Wollam, J.; Olefsky, J. M. GPR43 Potentiates Beta-Cell Function in Obesity. Diabetes 2015, 64, 3203-3217.
237. Priyadarshini, M.; Villa, S. R.; Fuller, M.; Wicksteed, B.; Mackay, C. R.; Alquier, T.; Poitout, V.; Mancebo, H.; Mirmira, R. G.; Gilchrist, A.; et al. An Acetate-Specific GPCR, FFAR2, Regulates Insulin Secretion. Mol. Endocrinol. 2015, 29, 1055-1066.
238. Tang, C.; Ahmed, K.; Gille, A.; Lu, S.; Grone, H. J.; Tunaru, S.; Offermanns, S. Loss of FFA2 and FFA3 Increases Insulin Secretion and Improves Glucose Tolerance in Type 2 Diabetes. Nat. Med. 2015, 21, 173-177.
239. Han, J. H.; Kim, I. S.; Jung, S. H.; Lee, S. G.; Son, H. Y.; Myung, C. S. The Effects of Propionate and Valerate on Insulin Responsiveness for Glucose Uptake in 3T3-L1 Adipocytes and C2C12 Myotubes Via G Protein-Coupled Receptor 41. PLoS One 2014, 9, e95268.
240. Xiong, Y.; Miyamoto, N.; Shibata, K.; Valasek, M. A.; Motoike, T.; Kedzierski, R. M.; Yanagisawa, M. Short-Chain Fatty Acids Stimulate Leptin Production in Adipocytes through the G Protein-Coupled Receptor GPR41. Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 1045-1050.
241. Hong, Y. H.; Nishimura, Y.; Hishikawa, D.; Tsuzuki, H.; Miyahara, H.; Gotoh, C.; Choi, K. C.; Feng, D. D.; Chen, C.; Lee, H. G.; et al. Acetate and Propionate Short Chain Fatty Acids Stimulate Adipogenesis Via GPCR43. Endocrinology 2005, 146, 5092-5099.
242. Zaibi, M. S.; Stocker, C. J.; O'Dowd, J.; Davies, A.; Bellahcene, M.; Cawthorne, M. A.; Brown, A. J.; Smith, D. M.; Arch, J. R. Roles of GPR41 and GPR43 in Leptin Secretory Responses of Murine Adipocytes to Short Chain Fatty Acids. FEBS Lett. 2010, 584, 2381-2386.
243. Inoue, D.; Kimura, I.; Wakabayashi, M.; Tsumoto, H.; Ozawa, K.; Hara, T.; Takei, Y.; Hirasawa, A.; Ishihama, Y.; Tsujimoto, G. Short-Chain Fatty Acid Receptor GPR41-Mediated Activation of Sympathetic Neurons Involves Synapsin 2b Phosphorylation. FEBS Lett. 2012, 586, 1547-1554.
244. Kimura, I.; Inoue, D.; Maeda, T.; Hara, T.; Ichimura, A.; Miyauchi, S.; Kobayashi, M.; Hirasawa, A.; Tsujimoto, G. Short-Chain Fatty Acids and Ketones Directly Regulate Sympathetic Nervous System Via G Protein-Coupled Receptor 41 (GPR41). Proc. Natl. Acad. Sci. U. S. A. 2011, 108, 8030-8035.
245. Lopez Soto, E. J.; Gambino, L. O.; Mustafa, E. R. Free Fatty Acid Receptor 3 Is a Key Target of Short Chain Fatty Acid. What Is the Impact on the Sympathetic Nervous System? Channels 2014, 8, 169-171.
246. Nohr, M. K.; Egerod, K. L.; Christiansen, S. H.; Gille, A.; Offermanns, S.; Schwartz, T. W.; Moller, M. Expression of the Short Chain Fatty Acid Receptor GPR41/FFAR3 in Autonomic and Somatic Sensory Ganglia. Neuroscience 2015, 290, 126-137.
247. Won, Y. J.; Lu, V. B.; Puhl, H. L., 3rd; Ikeda, S. R. Beta-Hydroxybutyrate Modulates N-Type Calcium Channels in Rat Sympathetic Neurons by Acting as an Agonist for the G-Protein-Coupled Receptor FFA3. J. Neurosci. 2013, 33, 19314-19325.
248. Bindels, L. B.; Porporato, P.; Dewulf, E. M.; Verrax, J.; Neyrinck, A. M.; Martin, J. C.; Scott, K. P.; Buc Calderon, P.; Feron, O.; Muccioli, G. G.; et al. Gut Microbiota-Derived Propionate Reduces Cancer Cell Proliferation in the Liver. Br. J. Cancer 2012, 107, 1337-1344.
249. Tang, Y.; Chen, Y.; Jiang, H.; Robbins, G. T.; Nie, D. GProtein-Coupled Receptor for Short-Chain Fatty Acids Suppresses Colon Cancer. Int. J. Cancer 2011, 128, 847-856.
250. Yonezawa, T.; Kobayashi, Y.; Obara, Y. Short-Chain Fatty Acids Induce Acute Phosphorylation of the P38 Mitogen-Activated Protein Kinase/Heat Shock Protein 27 Pathway Via GPR43 in the MCF-7 Human Breast Cancer Cell Line. Cell. Signalling 2007, 19, 185-193.
251. Liaw, C. W.; Connolly, D. T. Sequence Polymorphisms Provide a Common Consensus Sequence for GPR41 and GPR42. DNA Cell Biol. 2009, 28, 555-560.
252. Puhl, H. L., III; Won, Y. J.; Lu, V. B.; Ikeda, S. R. Human GPR42 Is a Transcribed Multisite Variant That Exhibits Copy Number Polymorphism and Is Functional When Heterologously Expressed. Sci. Rep. 2015, 5, 12880.
253. Handsaker, R. E.; Van Doren, V.; Berman, J. R.; Genovese, G.; Kashin, S.; Boettger, L. M.; McCarroll, S. A. Large Multiallelic Copy Number Variations in Humans. Nat. Genet. 2015, 47, 296-303.
254. Milligan, G.; Stoddart, L. A.; Smith, N. J. Agonism and Allosterism: The Pharmacology of the Free Fatty Acid Receptors FFA2 and FFA3. Br. J. Pharmacol. 2009, 158, 146-153.
255. Schmidt, J.; Smith, N. J.; Christiansen, E.; Tikhonova, I. G.; Grundmann, M.; Hudson, B. D.; Ward, R. J.; Drewke, C.; Milligan, G.; Kostenis, E.; et al. Selective Orthosteric Free Fatty Acid Receptor 2 (FFA2) Agonists: Identification of the Structural and Chemical Requirements for Selective Activation of FFA2 Versus FFA3. J. Biol. Chem. 2011, 286, 10628-10640.
256. Hudson, B. D.; Tikhonova, I. G.; Pandey, S. K.; Ulven, T.; Milligan, G. Extracellular Ionic Locks Determine Variation in Constitutive Activity and Ligand Potency between Species Orthologs of the Free Fatty Acid Receptors FFA2 and FFA3. J. Biol. Chem. 2012, 287, 41195-41209.
257. Sergeev, E.; Hansen, A. H.; Pandey, S. K.; MacKenzie, A. E.; Hudson, B. D.; Ulven, T.; Milligan, G. Non-Equivalence of Key Positively Charged Residues of the Free Fatty Acid 2 Receptor in the Recognition and Function of Agonist Versus Antagonist Ligands. J. Biol. Chem. 2016, 291, 303-317.
258. Psichas, A.; Sleeth, M. L.; Murphy, K. G.; Brooks, L.; Bewick, G. A.; Hanyaloglu, A. C.; Ghatei, M. A.; Bloom, S. R.; Frost, G. The Short Chain Fatty Acid Propionate Stimulates GLP-1 and Pyy Secretion Via Free Fatty Acid Receptor 2 in Rodents. Int. J. Obes. 2015, 39, 424-429.
259. Engelstoft, M. S.; Park, W. M.; Sakata, I.; Kristensen, L. V.; Husted, A. S.; Osborne-Lawrence, S.; Piper, P. K.; Walker, A. K.; Pedersen, M. H.; Nohr, M. K.; et al. Seven Transmembrane G Protein-Coupled Receptor Repertoire of Gastric Ghrelin Cells. Mol. Metab. 2013, 2, 376-392.
260. Canfora, E. E.; Jocken, J. W.; Blaak, E. E. Short-Chain Fatty Acids in Control of Body Weight and Insulin Sensitivity. Nat. Rev. Endocrinol. 2015, 11, 577-591.
261. Ge, H.; Li, X.; Weiszmann, J.; Wang, P.; Baribault, H.; Chen, J. L.; Tian, H.; Li, Y. Activation of G Protein-Coupled Receptor 43 in Adipocytes Leads to Inhibition of Lipolysis and Suppression of Plasma Free Fatty Acids. Endocrinology 2008, 149, 4519-4526.
262. Bjursell, M.; Admyre, T.; Goransson, M.; Marley, A. E.; Smith, D. M.; Oscarsson, J.; Bohlooly, Y. M. Improved Glucose Control and Reduced Body Fat Mass in Free Fatty Acid Receptor 2-Deficient Mice Fed a High-Fat Diet. Am. J. Physiol. Endocrinol. Metab. 2011, 300, E211-220.
263. Kimura, I.; Ozawa, K.; Inoue, D.; Imamura, T.; Kimura, K.; Maeda, T.; Terasawa, K.; Kashihara, D.; Hirano, K.; Tani, T.; et al. The Gut Microbiota Suppresses Insulin-Mediated Fat Accumulation Via the Short-Chain Fatty Acid Receptor GPR43. Nat. Commun. 2013, 4, 1829.
264. Dewulf, E. M.; Ge, Q.; Bindels, L. B.; Sohet, F. M.; Cani, P. D.; Brichard, S. M.; Delzenne, N. M. Evaluation of the Relationship between GPR43 and Adiposity in Human. Nutr. Metab. 2013, 10, 11.
265. Heimann, E.; Nyman, M.; Degerman, E. Propionic Acid and Butyric Acid Inhibit Lipolysis and De Novo Lipogenesis and Increase Insulin-Stimulated Glucose Uptake in Primary Rat Adipocytes. Adipocyte 2015, 4, 81-88.
266. Hoveyda, H.; Brantis, C. E.; Dutheuil, G.; Zoute, L.; Schils, D.; Bernard, J. Compounds, pharmaceutical composition and methods for use in treating metabolic disorders. International Patent application WO 2010/066682, June 17, 2010.
267. Maslowski, K. M.; Vieira, A. T.; Ng, A.; Kranich, J.; Sierro, F.; Yu, D.; Schilter, H. C.; Rolph, M. S.; Mackay, F.; Artis, D.; et al. Regulation of Inflammatory Responses by Gut Microbiota and Chemoattractant Receptor GPR43. Nature 2009, 461, 1282-1286.
268. Sina, C.; Gavrilova, O.; Forster, M.; Till, A.; Derer, S.; Hildebrand, F.; Raabe, B.; Chalaris, A.; Scheller, J.; Rehmann, A.; et al. G Protein-Coupled Receptor 43 Is Essential for Neutrophil Recruitment During Intestinal Inflammation. J. Immunol. 2009, 183, 7514-7522.
269. Vinolo, M. A.; Ferguson, G. J.; Kulkarni, S.; Damoulakis, G.; Anderson, K.; Bohlooly, Y. M.; Stephens, L.; Hawkins, P. T.; Curi, R. Scfas Induce Mouse Neutrophil Chemotaxis through the GPR43 Receptor. PLoS One 2011, 6, e21205.
270. Masui, R.; Sasaki, M.; Funaki, Y.; Ogasawara, N.; Mizuno, M.; Iida, A.; Izawa, S.; Kondo, Y.; Ito, Y.; Tamura, Y.; et al. G Protein-Coupled Receptor 43 Moderates Gut Inflammation through Cytokine Regulation from Mononuclear Cells. Inflamm. Bowel Dis. 2013, 19, 2848-2856.
271. Kim, M. H.; Kang, S. G.; Park, J. H.; Yanagisawa, M.; Kim, C. H. Short-Chain Fatty Acids Activate GPR41 and GPR43 on Intestinal Epithelial Cells to Promote Inflammatory Responses in Mice. Gastroenterology 2013, 145, 396-406 e391-310.
272. Kalliomaki, M.; Collado, M. C.; Salminen, S.; Isolauri, E. Early Differences in Fecal Microbiota Composition in Children May Predict Overweight. Am. J. Clin. Nutr. 2008, 87, 534-538.
273. Tuddenham, S.; Sears, C. L. The Intestinal Microbiome and Health. Curr. Opin. Infect. Dis. 2015, 28, 464-470.
274. Pluznick, J. L.; Protzko, R. J.; Gevorgyan, H.; Peterlin, Z.; Sipos, A.; Han, J.; Brunet, I.; Wan, L. X.; Rey, F.; Wang, T.; et al. Olfactory Receptor Responding to Gut Microbiota-Derived Signals Plays a Role in Renin Secretion and Blood Pressure Regulation. Proc. Natl. Acad. Sci. U. S. A. 2013, 110, 4410-4415.
275. Samuel, B. S.; Shaito, A.; Motoike, T.; Rey, F. E.; Backhed, F.; Manchester, J. K.; Hammer, R. E.; Williams, S. C.; Crowley, J.; Yanagisawa, M.; et al. Effects of the Gut Microbiota on Host Adiposity Are Modulated by the Short-Chain Fatty-Acid Binding G Protein-Coupled Receptor, GPR41. Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 16767-16772.
276. Smith, P. M.; Howitt, M. R.; Panikov, N.; Michaud, M.; Gallini, C. A.; Bohlooly, Y. M.; Glickman, J. N.; Garrett, W. S. The Microbial Metabolites, Short-Chain Fatty Acids, Regulate Colonic Treg Cell Homeostasis. Science 2013, 341, 569-573.
277. Trompette, A.; Gollwitzer, E. S.; Yadava, K.; Sichelstiel, A. K.; Sprenger, N.; Ngom-Bru, C.; Blanchard, C.; Junt, T.; Nicod, L. P.; Harris, N. L.; et al. Gut Microbiota Metabolism of Dietary Fiber Influences Allergic Airway Disease and Hematopoiesis. Nat. Med. 2014, 20, 159-166.
278. Vieira, A. T.; Macia, L.; Galvao, I.; Martins, F. S.; Canesso, M. C.; Amaral, F. A.; Garcia, C. C.; Maslowski, K. M.; De Leon, E.; Shim, D.; et al. A Role for Gut Microbiota and the Metabolite-Sensing Receptor GPR43 in a Murine Model of Gout. Arthritis Rheumatol. 2015, 67, 1646-1656.
279. Ulven, T. Short-Chain Free Fatty Acid Receptors FFA2/GPR43 and FFA3/GPR41 as New Potential Therapeutic Targets. Front. Endocrinol. (Lausanne, Switz.) 2012, 3, 111.
280. Urban, D. J.; Roth, B. L. Dreadds (Designer Receptors Exclusively Activated by Designer Drugs): Chemogenetic Tools with Therapeutic Utility. Annu. Rev. Pharmacol. Toxicol. 2015, 55, 399-417.
281. Wess, J.; Nakajima, K.; Jain, S. Novel Designer Receptors to Probe GPCR Signaling and Physiology. Trends Pharmacol. Sci. 2013, 34, 385-392.
282. Bolognini, D.; Tobin, A. B.; Milligan, G.; Moss, C. E. P. Mol. Pharmacol. 2016, 89, 388-398.
283. Patterson, E.; Cryan, J. F.; Fitzgerald, G. F.; Ross, R. P.; Dinan, T. G.; Stanton, C. Gut Microbiota, the Pharmabiotics They Produce and Host Health. Proc. Nutr. Soc. 2014, 73, 477-489.
284. Tan, J.; McKenzie, C.; Potamitis, M.; Thorburn, A. N.; Mackay, C. R.; Macia, L. The Role of Short-Chain Fatty Acids in Health and Disease. Adv. Immunol. 2014, 121, 91-119.
285. Brown, A. J.; Tsoulou, C.; Ward, E.; Gower, E.; Bhudia, N.; Chowdhury, F.; Dean, T. W.; Faucher, N.; Gangar, A.; Dowell, S. J. Pharmacological Properties of Acid N-Thiazolylamide FFA2 Agonists. Pharmacol. Res. Perspect. 2015, 3, e00141.
286. Hoveyda, H.; Brantis, C. E.; Dutheuil, G.; Zoute, L.; Schils, D.; Fraser, G. Compounds, pharmaceutical composition and methods for use in treating gastrointestinal disorders. International Patent application WO 2011/076732 A1, June 30, 2011.
287. Forbes, S.; Stafford, S.; Coope, G.; Heffron, H.; Real, K.; Newman, R.; Davenport, R.; Barnes, M.; Grosse, J.; Cox, H. Selective FFA2 Agonism Appears to Act Via Intestinal PYY to Reduce Transit and Food Intake but Does Not Improve Glucose Tolerance in Mouse Models. Diabetes 2015, 64, 3763-3771.
288. Brantis, C. E.; Ooms, F.; Bernard, J. Novel amino acid derivatives and their use as gpr43 receptor modulators. International Patent Application, WO2011/092284, Aug 4, 2011.
289. Pizzonero, M.; Dupont, S.; Babel, M.; Beaumont, S.; Bienvenu, N.; Blanque, R.; Cherel, L.; Christophe, T.; Crescenzi, B.; De Lemos, E.; et al. Discovery and Optimization of an Azetidine Chemical Series as a Free Fatty Acid Receptor 2 (FFA2) Antagonist: From Hit to Clinic. J. Med. Chem. 2014, 57, 10044-10057.
290. Vermeire, S.; K, V.; Knoflícek, V.; Reinisch, W.; Van Kaem, T.; Namour, F.; Beetens, J.; Vanhoutte, F. GLPG0974, an FFA2 Antagonist, in Ulcerative Colitis: Efficacy and Safety in a Multicenter Proof-of-Concept Study. Journal of Crohn's and Colitis 2015, 9, S39.
291. Park, B. O.; Kim, S. H.; Kong, G. Y.; Kim, D. H.; Kwon, M. S.; Lee, S. U.; Kim, M. O.; Cho, S.; Lee, S.; Lee, H. J.; et al. Selective Novel Inverse Agonists for Human GPR43 Augment GLP-1 Secretion. Eur. J. Pharmacol. 2016, 771, 1-9.
292. Lee, T.; Schwandner, R.; Swaminath, G.; Weiszmann, J.; Cardozo, M.; Greenberg, J.; Jaeckel, P.; Ge, H.; Wang, Y.; Jiao, X.; et al. Identification and Functional Characterization of Allosteric Agonists for the G Protein-Coupled Receptor FFA2. Mol. Pharmacol. 2008, 74, 1599-1609.
293. Smith, N. J.; Ward, R. J.; Stoddart, L. A.; Hudson, B. D.; Kostenis, E.; Ulven, T.; Morris, J. C.; Trankle, C.; Tikhonova, I. G.; Adams, D. R.; et al. Extracellular Loop 2 of the Free Fatty Acid Receptor 2 Mediates Allosterism of a Phenylacetamide Ago-Allosteric Modulator. Mol. Pharmacol. 2011, 80, 163-173.
294. Wang, Y.; Jiao, X.; Kayser, F.; Liu, J.; Wang, Z.; Wanska, M.; Greenberg, J.; Weiszmann, J.; Ge, H.; Tian, H.; et al. The First Synthetic Agonists of FFA2: Discovery and Sar of Phenylacetamides as Allosteric Modulators. Bioorg. Med. Chem. Lett. 2010, 20, 493-498.
295. Grundmann, M.; Tikhonova, I. G.; Hudson, B. D.; Smith, N. J.; Mohr, K.; Ulven, T.; Milligan, G.; Kenakin, T.; Kostenis, E. A Molecular Mechanism for Sequential Activation of a G Protein-Coupled Receptor. Cell Chem. Biol. 2016, 23, 392-403.
296. Taggart, A. K.; Kero, J.; Gan, X.; Cai, T. Q.; Cheng, K.; Ippolito, M.; Ren, N.; Kaplan, R.; Wu, K.; Wu, T. J.; et al. D)-Beta-Hydroxybutyrate Inhibits Adipocyte Lipolysis Via the Nicotinic Acid Receptor Puma-G. J. Biol. Chem. 2005, 280, 26649-26652.
297. Leonard, J. N.; Chu, Z. L.; Bruce, M. A.; Boatman, P. D. GPR41 and modulators thereof for the treatment of insulin-related disorders. International Patent Application WO 2006/052566, May 18, 2016.
298. Hudson, B. D.; Christiansen, E.; Murdoch, H.; Jenkins, L.; Hansen, A. H.; Madsen, O.; Ulven, T.; Milligan, G. Complex Pharmacology of Novel Allosteric Free Fatty Acid 3 Receptor Ligands. Mol. Pharmacol. 2014, 86, 200-210.
299. Schann, S.; Mayer, S.; Franchet, C.; Frauli, M.; Steinberg, E.; Thomas, M.; Baron, L.; Neuville, P. Chemical Switch of a Metabotropic Glutamate Receptor 2 Silent Allosteric Modulator into Dual Metabotropic Glutamate Receptor 2/3 Negative/Positive Allosteric Modulators. J. Med. Chem. 2010, 53, 8775-8779.
300. Hirasawa, A.; Tsumaya, K.; Awaji, T.; Katsuma, S.; Adachi, T.; Yamada, M.; Sugimoto, Y.; Miyazaki, S.; Tsujimoto, G. Free Fatty Acids Regulate Gut Incretin Glucagon-Like Peptide-1 Secretion through GPR120. Nat. Med. 2005, 11, 90-94.
301. Hara, T.; Hirasawa, A.; Sun, Q.; Sadakane, K.; Itsubo, C.; Iga, T.; Adachi, T.; Koshimizu, T. A.; Hashimoto, T.; Asakawa, Y.; et al. Novel Selective Ligands for Free Fatty Acid Receptors GPR120 and GPR40. Naunyn-Schmiedeberg's Arch. Pharmacol. 2009, 380, 247-255.
302. Moore, K.; Zhang, Q.; Murgolo, N.; Hosted, T.; Duffy, R. Cloning, Expression, and Pharmacological Characterization of the GPR120 Free Fatty Acid Receptor from Cynomolgus Monkey: Comparison with Human GPR120 Splice Variants. Comp. Biochem. Physiol., Part B: Biochem. Mol. Biol. 2009, 154, 419-426.
303. Watson, S. J.; Brown, A. J.; Holliday, N. D. Differential Signaling by Splice Variants of the Human Free Fatty Acid Receptor GPR120. Mol. Pharmacol. 2012, 81, 631-642.
304. Stone, V. M.; Dhayal, S.; Brocklehurst, K. J.; Lenaghan, C.; Sorhede Winzell, M.; Hammar, M.; Xu, X.; Smith, D. M.; Morgan, N. G. GPR120 (FFAR4) Is Preferentially Expressed in Pancreatic Delta Cells and Regulates Somatostatin Secretion from Murine Islets of Langerhans. Diabetologia 2014, 57, 1182-1191.
305. Sanchez-Reyes, O. B.; Romero-Avila, M. T.; Castillo-Badillo, J. A.; Takei, Y.; Hirasawa, A.; Tsujimoto, G.; Villalobos-Molina, R.; Garcia-Sainz, J. A. Free Fatty Acids and Protein Kinase C Activation Induce GPR120 (Free Fatty Acid Receptor 4) Phosphorylation. Eur. J. Pharmacol. 2014, 723, 368-374.
306. Butcher, A. J.; Hudson, B. D.; Shimpukade, B.; Alvarez-Curto, E.; Prihandoko, R.; Ulven, T.; Milligan, G.; Tobin, A. B. Concomitant Action of Structural Elements and Receptor Phosphorylation Determines Arrestin-3 Interaction with the Free Fatty Acid Receptor FFA4. J. Biol. Chem. 2014, 289, 18451-18465.
307. Burns, R. N.; Singh, M.; Senatorov, I. S.; Moniri, N. H. Mechanisms of Homologous and Heterologous Phosphorylation of FFA Receptor 4 (GPR120): GRK6 and PKC Mediated Phosphorylation of Thr347, Ser350, and Ser357 in the C-Terminal Tail. Biochem. Pharmacol. 2014, 87, 650-659.
308. Burns, R. N.; Moniri, N. H. Agonism with the Omega-3 Fatty Acids Alpha-Linolenic Acid and Docosahexaenoic Acid Mediates Phosphorylation of Both the Short and Long Isoforms of the Human GPR120 Receptor. Biochem. Biophys. Res. Commun. 2010, 396, 1030-1035.
309. Prihandoko, R.; Alvarez-Curto, E.; Hudson, B. D.; Butcher, A. J.; Ulven, T.; Miller, A. M.; Tobin, A. B.; Milligan, G. Distinct Phosphorylation Clusters Determine the Signaling Outcome of Free Fatty Acid Receptor 4/G Protein-Coupled Receptor 120. Mol. Pharmacol. 2016, 89, 505-520.
310. Hudson, B. D.; Shimpukade, B.; Milligan, G.; Ulven, T. The Molecular Basis of Ligand Interaction at Free Fatty Acid Receptor 4 (FFA4/GPR120). J. Biol. Chem. 2014, 289, 20345-20358.
311. Milligan, G.; Alvarez-Curto, E.; Watterson, K. R.; Ulven, T.; Hudson, B. D. Characterizing Pharmacological Ligands to Study the Long-Chain Fatty Acid Receptors GPR40/FFA1 and GPR120/FFA4. Br. J. Pharmacol. 2015, 172, 3254-3265.
312. Oh, D. Y.; Talukdar, S.; Bae, E. J.; Imamura, T.; Morinaga, H.; Fan, W.; Li, P.; Lu, W. J.; Watkins, S. M.; Olefsky, J. M. GPR120 Is an Omega-3 Fatty Acid Receptor Mediating Potent Anti-Inflammatory and Insulin-Sensitizing Effects. Cell 2010, 142, 687-698.
313. Tanaka, T.; Yano, T.; Adachi, T.; Koshimizu, T. A.; Hirasawa, A.; Tsujimoto, G. Cloning and Characterization of the Rat Free Fatty Acid Receptor GPR120: In Vivo Effect of the Natural Ligand on GLP-1 Secretion and Proliferation of Pancreatic Beta Cells. Naunyn-Schmiedeberg's Arch. Pharmacol. 2008, 377, 515-522.
314. Miyauchi, S.; Hirasawa, A.; Iga, T.; Liu, N.; Itsubo, C.; Sadakane, K.; Hara, T.; Tsujimoto, G. Distribution and Regulation of Protein Expression of the Free Fatty Acid Receptor GPR120. Naunyn-Schmiedeberg's Arch. Pharmacol. 2009, 379, 427-434.
315. Iwasaki, K.; Harada, N.; Sasaki, K.; Yamane, S.; Iida, K.; Suzuki, K.; Hamasaki, A.; Nasteska, D.; Shibue, K.; Joo, E.; et al. Free Fatty Acid Receptor GPR120 Is Highly Expressed in Enteroendocrine K Cells of the Upper Small Intestine and Has a Critical Role in Gip Secretion after Fat Ingestion. Endocrinology 2015, 156, 837-846.
316. Paulsen, S. J.; Larsen, L. K.; Hansen, G.; Chelur, S.; Larsen, P. J.; Vrang, N. Expression of the Fatty Acid Receptor GPR120 in the Gut of Diet-Induced-Obese Rats and Its Role in GLP-1 Secretion. PLoS One 2014, 9, e88227.
317. Duca, F. A.; Swartz, T. D.; Sakar, Y.; Covasa, M. Decreased Intestinal Nutrient Response in Diet-Induced Obese Rats: Role of Gut Peptides and Nutrient Receptors. Int. J. Obes. 2013, 37, 375-381.
318. Fam, B. C.; Sgambellone, R.; Ruan, Z.; Proietto, J.; Andrikopoulos, S. Contribution of the Hypothalamus and Gut to Weight Gain Susceptibility and Resistance in Mice. J. Endocrinol. 2015, 225, 191-204.
319. Little, T. J.; Isaacs, N. J.; Young, R. L.; Ott, R.; Nguyen, N. Q.; Rayner, C. K.; Horowitz, M.; Feinle-Bisset, C. Characterization of Duodenal Expression and Localization of Fatty Acid-Sensing Receptors in Humans: Relationships with Body Mass Index. Am. J. Physiol. Gastrointest. Liver Physiol. 2014, 307, G958-967.
320. Fredborg, M.; Theil, P. K.; Jensen, B. B.; Purup, S. G Protein-Coupled Receptor120 (GPR120) Transcription in Intestinal Epithelial Cells Is Significantly Affected by Bacteria Belonging to the Bacteroides, Proteobacteria, and Firmicutes Phyla. J. Anim. Sci. 2012, 90 (Suppl 4), 10-12.
321. Gotoh, C.; Hong, Y. H.; Iga, T.; Hishikawa, D.; Suzuki, Y.; Song, S. H.; Choi, K. C.; Adachi, T.; Hirasawa, A.; Tsujimoto, G.; et al. The Regulation of Adipogenesis through GPR120. Biochem. Biophys. Res. Commun. 2007, 354, 591-597.
322. Ichimura, A.; Hirasawa, A.; Poulain-Godefroy, O.; Bonnefond, A.; Hara, T.; Yengo, L.; Kimura, I.; Leloire, A.; Liu, N.; Iida, K.; et al. Dysfunction of Lipid Sensor GPR120 Leads to Obesity in Both Mouse and Human. Nature 2012, 483, 350-354.
323. Rodriguez-Pacheco, F.; Garcia-Serrano, S.; Garcia-Escobar, E.; Gutierrez-Repiso, C.; Garcia-Arnes, J.; Valdes, S.; Gonzalo, M.; Soriguer, F.; Moreno-Ruiz, F. J.; Rodriguez-Canete, A.; et al. Effects of Obesity/Fatty Acids on the Expression of GPR120. Mol. Nutr. Food Res. 2014, 58, 1852-1860.
324. Trayhurn, P.; Denyer, G. Mining Microarray Datasets in Nutrition: Expression of the GPR120 (n-3 Fatty Acid Receptor/Sensor) Gene Is Down-Regulated in Human Adipocytes by Macrophage Secretions. J. Nutr. Sci. 2012, 1, e3.
325. Oh, D. Y.; Walenta, E.; Akiyama, T. E.; Lagakos, W. S.; Lackey, D.; Pessentheiner, A. R.; Sasik, R.; Hah, N.; Chi, T. J.; Cox, J. M.; et al. A GPR120-Selective Agonist Improves Insulin Resistance and Chronic Inflammation in Obese Mice. Nat. Med. 2014, 20, 942-947.
326. Mizuta, K.; Zhang, Y.; Mizuta, F.; Hoshijima, H.; Shiga, T.; Masaki, E.; Emala, C. W., Sr. Novel Identification of the Free Fatty Acid Receptor FFAR1 That Promotes Contraction in Airway Smooth Muscle. Am. J. Physiol. Lung Cell Mol. Physiol. 2015, 309, L970-982.
327. Suckow, A. T.; Polidori, D.; Yan, W.; Chon, S.; Ma, J. Y.; Leonard, J.; Briscoe, C. P. Alteration of the Glucagon Axis in GPR120 (FFAR4) Knockout Mice a Role for GPR120 in Glucagon Secretion. J. Biol. Chem. 2014, 289, 15751-15763.
328. Moran, B. M.; Abdel-Wahab, Y. H. A.; Flatt, P. R.; McKillop, A. M. Evaluation of the Insulin-Releasing and Glucose-Lowering Effects of GPR120 Activation in Pancreatic Beta-Cells. Diabetes, Obes. Metab. 2014, 16, 1128-1139.
329. Taneera, J.; Lang, S.; Sharma, A.; Fadista, J.; Zhou, Y.; Ahlqvist, E.; Jonsson, A.; Lyssenko, V.; Vikman, P.; Hansson, O.; et al. A Systems Genetics Approach Identifies Genes and Pathways for Type 2 Diabetes in Human Islets. Cell Metab. 2012, 16, 122-134.
330. Matsumura, S.; Mizushige, T.; Yoneda, T.; Iwanaga, T.; Tsuzuki, S.; Inoue, K.; Fushiki, T. GPR Expression in the Rat Taste Bud Relating to Fatty Acid Sensing. Biomed. Res. 2007, 28, 49-55.
331. Galindo, M. M.; Voigt, N.; Stein, J.; van Lengerich, J.; Raguse, J. D.; Hofmann, T.; Meyerhof, W.; Behrens, M. G Protein-Coupled Receptors in Human Fat Taste Perception. Chem. Senses 2012, 37, 123-139.
332. Cartoni, C.; Yasumatsu, K.; Ohkuri, T.; Shigemura, N.; Yoshida, R.; Godinot, N.; le Coutre, J.; Ninomiya, Y.; Damak, S. Taste Preference for Fatty Acids Is Mediated by GPR40 and GPR120. J. Neurosci. 2010, 30, 8376-8382.
333. Martin, C.; Passilly-Degrace, P.; Gaillard, D.; Merlin, J. F.; Chevrot, M.; Besnard, P. The Lipid-Sensor Candidates CD36 and GPR120 Are Differentially Regulated by Dietary Lipids in Mouse Taste Buds: Impact on Spontaneous Fat Preference. PLoS One 2011, 6, e24014.
334. Ozdener, M. H.; Subramaniam, S.; Sundaresan, S.; Sery, O.; Hashimoto, T.; Asakawa, Y.; Besnard, P.; Abumrad, N. A.; Khan, N. A. Cd36-And GPR120-Mediated Ca2+ Signaling in Human Taste Bud Cells Mediates Differential Responses to Fatty Acids and Is Altered in Obese Mice. Gastroenterology 2014, 146, 995-1005.
335. Ancel, D.; Bernard, A.; Subramaniam, S.; Hirasawa, A.; Tsujimoto, G.; Hashimoto, T.; Passilly-Degrace, P.; Khan, N. A.; Besnard, P. The Oral Lipid Sensor GPR120 Is Not Indispensable for the Orosensory Detection of Dietary Lipids in Mice. J. Lipid Res. 2015, 56, 369-378.
336. Sclafani, A.; Zukerman, S.; Ackroff, K. GPR40 and GPR120 Fatty Acid Sensors Are Critical for Postoral but Not Oral Mediation of Fat Preferences in the Mouse. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2013, 305, R1490-1497.
337. Liu, Z.; Hopkins, M. M.; Zhang, Z. H.; Quisenberry, C. B.; Fix, L. C.; Galvan, B. M.; Meier, K. E. Omega-3 Fatty Acids and Other FFA4 Agonists Inhibit Growth Factor Signaling in Human Prostate Cancer Cells. J. Pharmacol. Exp. Ther. 2015, 352, 380-394.
338. Fukushima, K.; Yamasaki, E.; Ishii, S.; Tomimatsu, A.; Takahashi, K.; Hirane, M.; Fukushima, N.; Honoki, K.; Tsujiuchi, T. Different Roles of GPR120 and GPR40 in the Acquisition of Malignant Properties in Pancreatic Cancer Cells. Biochem. Biophys. Res. Commun. 2015, 465, 512-515.
339. Wu, Q.; Wang, H.; Zhao, X.; Shi, Y.; Jin, M.; Wan, B.; Xu, H.; Cheng, Y.; Ge, H.; Zhang, Y. Identification of G-Protein-Coupled Receptor 120 as a Tumor-Promoting Receptor That Induces Angiogenesis and Migration in Human Colorectal Carcinoma. Oncogene 2013, 32, 5541-5550.
340. Vestmar, M. A.; Andersson, E. A.; Christensen, C. R.; Hauge, M.; Glumer, C.; Linneberg, A.; Witte, D. R.; Jorgensen, M. E.; Christensen, C.; Brandslund, I.; et al. Functional and Genetic Epidemiological Characterisation of the FFAR4 (GPR120) p.R270H Variant in the Danish Population. J. Med. Genet. 2016.
341. Bonnefond, A.; Lamri, A.; Leloire, A.; Vaillant, E.; Roussel, R.; Levy-Marchal, C.; Weill, J.; Galan, P.; Hercberg, S.; Ragot, S.; et al. Contribution of the Low-Frequency, Loss-of-Function p.R270H Mutation in FFAR4 (GPR120) to Increased Fasting Plasma Glucose Levels. J. Med. Genet. 2015, 52, 595-598.
342. Oh, D. Y.; Olefsky, J. M. Omega 3 Fatty Acids and GPR120. Cell Metab. 2012, 15, 564-565.
343. Habib, A. M.; Richards, P.; Rogers, G. J.; Reimann, F.; Gribble, F. M. Co-Localisation and Secretion of Glucagon-Like Peptide 1 and Peptide YY from Primary Cultured Human L Cells. Diabetologia 2013, 56, 1413-1416.
344. Katsuma, S.; Hatae, N.; Yano, T.; Ruike, Y.; Kimura, M.; Hirasawa, A.; Tsujimoto, G. Free Fatty Acids Inhibit Serum Deprivation-Induced Apoptosis through GPR120 in a Murine Enteroendocrine Cell Line Stc-1. J. Biol. Chem. 2005, 280, 19507-19515.
345. Martin, C.; Passilly-Degrace, P.; Chevrot, M.; Ancel, D.; Sparks, S. M.; Drucker, D. J.; Besnard, P. Lipid-Mediated Release of GLP-1 by Mouse Taste Buds from Circumvallate Papillae: Putative Involvement of GPR120 and Impact on Taste Sensitivity. J. Lipid Res. 2012, 53, 2256-2265.
346. Tanaka, T.; Katsuma, S.; Adachi, T.; Koshimizu, T. A.; Hirasawa, A.; Tsujimoto, G. Free Fatty Acids Induce Cholecystokinin Secretion through GPR120. Naunyn-Schmiedeberg's Arch. Pharmacol. 2008, 377, 523-527.
347. Lu, X.; Zhao, X.; Feng, J.; Liou, A. P.; Anthony, S.; Pechhold, S.; Sun, Y.; Lu, H.; Wank, S. Postprandial Inhibition of Gastric Ghrelin Secretion by Long-Chain Fatty Acid through GPR120 in Isolated Gastric Ghrelin Cells and Mice. Am. J. Physiol. Gastrointest. Liver Physiol. 2012, 303, G367-376.
348. Gong, Z.; Yoshimura, M.; Aizawa, S.; Kurotani, R.; Zigman, J. M.; Sakai, T.; Sakata, I. G Protein-Coupled Receptor 120 Signaling Regulates Ghrelin Secretion in Vivo and in Vitro. American Journal of Physiology-Endocrinology and Metabolism 2014, 306, E28-E35.
349. Liu, D.; Wang, L.; Meng, Q.; Kuang, H.; Liu, X. G-Protein Coupled Receptor 120 Is Involved in Glucose Metabolism in Fat Cells. Cell. Mol. Biol. (Noisy-le-grand) 2012, No. Suppl 58, OL1757-1762.
350. Cranmer-Byng, M. M.; Liddle, D. M.; De Boer, A. A.; Monk, J. M.; Robinson, L. E. Proinflammatory Effects of Arachidonic Acid in a Lipopolysaccharide-Induced Inflammatory Microenvironment in 3T3-L1 Adipocytes in Vitro. Appl. Physiol., Nutr., Metab. 2015, 40, 142-154.
351. Hasan, A. U.; Ohmori, K.; Konishi, K.; Igarashi, J.; Hashimoto, T.; Kamitori, K.; Yamaguchi, F.; Tsukamoto, I.; Uyama, T.; Ishihara, Y.; et al. Eicosapentaenoic Acid Upregulates VEGF-A through Both GPR120 and Ppargamma Mediated Pathways in 3T3-L1 Adipocytes. Mol. Cell. Endocrinol. 2015, 406, 10-18.
352. Calder, P. C. Marine Omega-3 Fatty Acids and Inflammatory Processes: Effects, Mechanisms and Clinical Relevance. Biochim. Biophys. Acta, Mol. Cell Biol. Lipids 2015, 1851, 469-484.
353. Im, D. S. Functions of Omega-3 Fatty Acids and FFA4 (GPR120) in Macrophages. Eur. J. Pharmacol. 2015.10.1016/j.ejphar.2015.03.094 (354)
354. Li, X.; Yu, Y.; Funk, C. D. Cyclooxygenase-2 Induction in Macrophages Is Modulated by Docosahexaenoic Acid Via Interactions with Free Fatty Acid Receptor 4 (FFA4). FASEB J. 2013, 27, 4987-4997.
355. Liu, Y.; Chen, L. Y.; Sokolowska, M.; Eberlein, M.; Alsaaty, S.; Martinez-Anton, A.; Logun, C.; Qi, H. Y.; Shelhamer, J. H. The Fish Oil Ingredient, Docosahexaenoic Acid, Activates Cytosolic Phospholipase a(2) Via GPR120 Receptor to Produce Prostaglandin E(2) and Plays an Anti-Inflammatory Role in Macrophages. Immunology 2014, 143, 81-95.
356. Frolov, A.; Yang, L.; Dong, H.; Hammock, B. D.; Crofford, L. J. Anti-Inflammatory Properties of Prostaglandin E2: Deletion of Microsomal Prostaglandin E Synthase-1 Exacerbates Non-Immune Inflammatory Arthritis in Mice. Prostaglandins, Leukotrienes Essent. Fatty Acids 2013, 89, 351-358.
357. Williams-Bey, Y.; Boularan, C.; Vural, A.; Huang, N. N.; Hwang, I. Y.; Shan-Shi, C.; Kehrl, J. H. Omega-3 Free Fatty Acids Suppress Macrophage Inflammasome Activation by Inhibiting Nf-Kappab Activation and Enhancing Autophagy. PLoS One 2014, 9, e97957.
358. Yan, Y.; Jiang, W.; Spinetti, T.; Tardivel, A.; Castillo, R.; Bourquin, C.; Guarda, G.; Tian, Z.; Tschopp, J.; Zhou, R. Omega-3 Fatty Acids Prevent Inflammation and Metabolic Disorder through Inhibition of NLRP3 Inflammasome Activation. Immunity 2013, 38, 1154-1163.
359. Shoelson, S. E.; Lee, J.; Goldfine, A. B. Inflammation and Insulin Resistance. J. Clin. Invest. 2006, 116, 1793-1801.
360. Bjursell, M.; Xu, X.; Admyre, T.; Bottcher, G.; Lundin, S.; Nilsson, R.; Stone, V. M.; Morgan, N. G.; Lam, Y. Y.; Storlien, L. H.; et al. The Beneficial Effects of N-3 Polyunsaturated Fatty Acids on Diet Induced Obesity and Impaired Glucose Control Do Not Require GPR120. PLoS One 2014, 9, e114942.
361. Chao, C. Y.; Lii, C. K.; Ye, S. Y.; Li, C. C.; Lu, C. Y.; Lin, A. H.; Liu, K. L.; Chen, H. W. Docosahexaenoic Acid Inhibits Vascular Endothelial Growth Factor (VEGF)-Induced Cell Migration Via the GPR120/PP2A/ERL1/2/eNOS Signaling Pathway in Human Umbilical Vein Endothelial Cells. J. Agric. Food Chem. 2014, 62, 4152-4158.
362. Kim, N.; Lee, J. O.; Lee, H. J.; Kim, H. I.; Kim, J. K.; Lee, Y. W.; Lee, S. K.; Kim, S. J.; Park, S. H.; Kim, H. S. Endogenous Ligand for GPR120, Docosahexaenoic Acid, Exerts Benign Metabolic Effects on the Skeletal Muscles Via Amp-Activated Protein Kinase Pathway. J. Biol. Chem. 2015, 290, 20438-20447.
363. Konno, Y.; Ueki, S.; Takeda, M.; Kobayashi, Y.; Tamaki, M.; Moritoki, Y.; Oyamada, H.; Itoga, M.; Kayaba, H.; Omokawa, A.; et al. Functional Analysis of Free Fatty Acid Receptor GPR120 in Human Eosinophils: Implications in Metabolic Homeostasis. PLoS One 2015, 10, e0120386.
364. Kim, H. J.; Yoon, H. J.; Kim, B. K.; Kang, W. Y.; Seong, S. J.; Lim, M. S.; Kim, S. Y.; Yoon, Y. R. G Protein-Coupled Receptor 120 Signaling Negatively Regulates Osteoclast Differentiation, Survival, and Function. J. Cell. Physiol. 2016, 231, 844-851.
365. Suzuki, T.; Igari, S.; Hirasawa, A.; Hata, M.; Ishiguro, M.; Fujieda, H.; Itoh, Y.; Hirano, T.; Nakagawa, H.; Ogura, M.; et al. Identification of G Protein-Coupled Receptor 120-Selective Agonists Derived from PPARγ Agonists. J. Med. Chem. 2008, 51, 7640-7644.
366. Sun, Q.; Hirasawa, A.; Hara, T.; Kimura, I.; Adachi, T.; Awaji, T.; Ishiguro, M.; Suzuki, T.; Miyata, N.; Tsujimoto, G. Structure-Activity Relationships of GPR120 Agonists Based on a Docking Simulation. Mol. Pharmacol. 2010, 78, 804-810.
367. Formicola, R.; Pevarello, P.; Kuhn, C.; Liberati, C.; Piscitelli, F.; Sodano, M. FFA4/GPR120 Agonists: A Survey of the Recent Patent Literature. Pharm. Pat. Anal. 2015, 4, 443-451.
368. Sparks, S. M.; Chen, G.; Collins, J. L.; Danger, D.; Dock, S. T.; Jayawickreme, C.; Jenkinson, S.; Laudeman, C.; Leesnitzer, M. A.; Liang, X.; et al. Identification of Diarylsulfonamides as Agonists of the Free Fatty Acid Receptor 4 (FFA4/GPR120). Bioorg. Med. Chem. Lett. 2014, 24, 3100-3103.
369. Shi, D. F.; Song, J.; Ma, J.; Novack, A.; Pham, P.; Nashashibi, I.; Rabbat, C. J.; Xin, C. GPR120 Receptor Agonists And Uses Thereof. International Patent Application WO 2010/080537, July 15, 2010.
370. Egerod, K. L.; Engelstoft, M. S.; Lund, M. L.; Grunddal, K. V.; Zhao, M.; Barir-Jensen, D.; Nygaard, E. B.; Petersen, N.; Holst, J. J.; Schwartz, T. W. Transcriptional and Functional Characterization of the G Protein-Coupled Receptor Repertoire of Gastric Somatostatin Cells. Endocrinology 2015, 156, 3909-3923.
371. Greenhill, C. Diabetes: GPR120 Agonist Has Anti-Inflammatory and Insulin-Sensitizing Effects. Nat. Rev. Endocrinol. 2014, 10, 510.
372. Mo, X. L.; Wei, H. K.; Peng, J.; Tao, Y. X. Free Fatty Acid Receptor GPR120 and Pathogenesis of Obesity and Type 2 Diabetes Mellitus. Prog. Mol. Biol. Transl. Sci. 2013, 114, 251-276.
373. Talukdar, S.; Olefsky, J. M.; Osborn, O. Targeting GPR120 and Other Fatty Acid-Sensing GPCRs Ameliorates Insulin Resistance and Inflammatory Diseases. Trends Pharmacol. Sci. 2011, 32, 543-550.
374. Rasmussen, S. G.; Choi, H. J.; Fung, J. J.; Pardon, E.; Casarosa, P.; Chae, P. S.; Devree, B. T.; Rosenbaum, D. M.; Thian, F. S.; Kobilka, T. S.; et al. Structure of a Nanobody-Stabilized Active State of the β2 Adrenoceptor. Nature 2011, 469, 175-180.
375. Li, A.; Yang, D.; Zhu, M.; Tsai, K. C.; Xiao, K. H.; Yu, X.; Sun, J.; Du, L. Discovery of Novel FFA4 (GPR120) Receptor Agonists with Beta-Arrestin2-Biased Characteristics. Future Med. Chem. 2015, 7, 2429-2437.
376. Yousefi, S.; Cooper, P. R.; Potter, S. L.; Mueck, B.; Jarai, G. Cloning and Expression Analysis of a Novel G-Protein-Coupled Receptor Selectively Expressed on Granulocytes. J. Leukoc. Biol. 2001, 69, 1045-1052.
377. Wang, J.; Wu, X.; Simonavicius, N.; Tian, H.; Ling, L. Medium-Chain Fatty Acids as Ligands for Orphan G Protein-Coupled Receptor GPR84. J. Biol. Chem. 2006, 281, 34457-34464.
378. Suzuki, M.; Takaishi, S.; Nagasaki, M.; Onozawa, Y.; Iino, I.; Maeda, H.; Komai, T.; Oda, T. Medium-Chain Fatty Acid-Sensing Receptor, GPR84, Is a Proinflammatory Receptor. J. Biol. Chem. 2013, 288, 10684-10691.
379. Nicol, L. S.; Dawes, J. M.; La Russa, F.; Didangelos, A.; Clark, A. K.; Gentry, C.; Grist, J.; Davies, J. B.; Malcangio, M.; McMahon, S. B. The Role of G-Protein Receptor 84 in Experimental Neuropathic Pain. J. Neurosci. 2015, 35, 8959-8969.
380. Audoy-Remus, J.; Bozoyan, L.; Dumas, A.; Filali, M.; Lecours, C.; Lacroix, S.; Rivest, S.; Tremblay, M. E.; Vallieres, L. GPR84 Deficiency Reduces Microgliosis, but Accelerates Dendritic Degeneration and Cognitive Decline in a Mouse Model of Alzheimer's Disease. Brain, Behav., Immun. 2015, 46, 112-120.
381. Perez, C. J.; Dumas, A.; Vallieres, L.; Guenet, J. L.; Benavides, F. Several Classical Mouse Inbred Strains, Including DBA/2, NOD/Lt, FVB/N, and SJL/J, Carry a Putative Loss-of-Function Allele of GPR84. J. Hered. 2013, 104, 565-571.
382. Takeda, S.; Yamamoto, A.; Okada, T.; Matsumura, E.; Nose, E.; Kogure, K.; Kojima, S.; Haga, T. Identification of Surrogate Ligands for Orphan G Protein-Coupled Receptors. Life Sci. 2003, 74, 367-377.
383. Brys, R. C. S.; Dupont, S. Screening methods to identify compounds useful in the prevention and/or treatment of inflammatory conditions. International Patent Application WO2013092793 A1, June 27, 2013.
384. Ahn, K. S.; Sethi, G.; Aggarwal, B. B. Embelin, an Inhibitor of X Chromosome-Linked Inhibitor-of-Apoptosis Protein, Blocks Nuclear Factor-Kappab (NF-κB) Signaling Pathway Leading to Suppression of Nf-Kappab-Regulated Antiapoptotic and Metastatic Gene Products. Mol. Pharmacol. 2006, 71, 209-219.
385. Zhang, Q.; Yang, H.; Li, J.; Xie, X. Discovery and Characterization of a Novel Small Molecule Agonist for Medium-Chain Free Fatty Acid Receptor GPR84. J. Pharmacol. Exp. Ther. 2016, 357, 337.
386. Liu, Y.; Zhang, Q.; Chen, L.-H.; Yang, H.; Lu, W.; Xie, X.; Nan, F. J. Design and Synthesis of 2-Alkylpyrimidine-4, 6-Diol and 6-Alkylpyridine-2, 4-Diol as Potent GPR84 Agonists. ACS Med. Chem. Lett. 2016.
387. Vanhoutte, F.; Dupont, S.; Van Kaem, T.; Gouy, M. H.; Blanque, R.; Brys, R.; Vandeghinste, N.; Gheyle, L.; Haazen, W.; van 't Klooster, G.; et al. Human Safety, Pharmacokinetics and Pharmacodynamics of the GPR84 Antagonist GLPG1205, a Potential New Approach to Treat Ibd. Journal of Crohn's and Colitis 2015, 9, S387-S387.
388. Nikaido, Y.; Koyama, Y.; Yoshikawa, Y.; Furuya, T.; Takeda, S. Mutation Analysis and Molecular Modeling for the Investigation of Ligand-Binding Modes of GPR84. J. Biochem. 2015, 157, 311-320.
389. Busse, D.; Kudella, P.; Gruning, N. M.; Gisselmann, G.; Stander, S.; Luger, T.; Jacobsen, F.; Steinstrasser, L.; Paus, R.; Gkogkolou, P.; et al. A Synthetic Sandalwood Odorant Induces Wound-Healing Processes in Human Keratinocytes Via the Olfactory Receptor Or2at4. J. Invest. Dermatol. 2014, 134, 2823-2832.
390. Griffin, C. A.; Kafadar, K. A.; Pavlath, G. K. MOR23 Promotes Muscle Regeneration and Regulates Cell Adhesion and Migration. Dev. Cell 2009, 17, 649-661.
391. Gu, X.; Karp, P. H.; Brody, S. L.; Pierce, R. A.; Welsh, M. J.; Holtzman, M. J.; Ben-Shahar, Y. Chemosensory Functions for Pulmonary Neuroendocrine Cells. Am. J. Respir. Cell Mol. Biol. 2014, 50, 637-646.
392. Pluznick, J. L.; Zou, D. J.; Zhang, X.; Yan, Q.; Rodriguez-Gil, D. J.; Eisner, C.; Wells, E.; Greer, C. A.; Wang, T.; Firestein, S.; et al. Functional Expression of the Olfactory Signaling System in the Kidney. Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 2059-2064.
393. Pluznick, J. A Novel Scfa Receptor, the Microbiota, and Blood Pressure Regulation. Gut Microbes 2014, 5, 202-207.
394. Fleischer, J.; Bumbalo, R.; Bautze, V.; Strotmann, J.; Breer, H. Expression of Odorant Receptor Olfr78 in Enteroendocrine Cells of the Colon. Cell Tissue Res. 2015, 361, 697-710.
395. Chang, A. J.; Ortega, F. E.; Riegler, J.; Madison, D. V.; Krasnow, M. A. Oxygen Regulation of Breathing through an Olfactory Receptor Activated by Lactate. Nature 2015, 527, 240-244.
396. Graff, E. C.; Fang, H.; Wanders, D.; Judd, R. L. Anti-Inflammatory Effects of the Hydroxycarboxylic Acid Receptor 2. Metab., Clin. Exp. 2016, 65, 102-113.
397. Thangaraju, M.; Cresci, G. A.; Liu, K.; Ananth, S.; Gnanaprakasam, J. P.; Browning, D. D.; Mellinger, J. D.; Smith, S. B.; Digby, G. J.; Lambert, N. A.; et al. GPR109A Is a G-Protein-Coupled Receptor for the Bacterial Fermentation Product Butyrate and Functions as a Tumor Suppressor in Colon. Cancer Res. 2009, 69, 2826-2832.
398. Macia, L.; Tan, J.; Vieira, A. T.; Leach, K.; Stanley, D.; Luong, S.; Maruya, M.; McKenzie, C. I.; Hijikata, A.; Wong, C. Metabolite-Sensing Receptors GPR43 and GPR109a Facilitate Dietary Fibre-Induced Gut Homeostasis through Regulation of the Inflammasome. Nat. Commun. 2015, 6, 6734.
399. Boatman, P. D.; Lauring, B.; Schrader, T. O.; Kasem, M.; Johnson, B. R.; Skinner, P.; Jung, J. K.; Xu, J.; Cherrier, M. C.; Webb, P. J.; et al. 1aR, 5aR)1a, 3, 5, 5a-Tetrahydro-1H-2, 3-Diaza-Cyclopropa-[a]Pentalene-4-Carboxylic Acid (MK-1903): A Potent GPR109a Agonist That Lowers Free Fatty Acids in Humans. J. Med. Chem. 2012, 55, 3644-3666.
400. Palani, A.; Rao, A. U.; Chen, X.; Huang, X. H.; Su, J.; Tang, H. Q.; Huang, Y.; Qin, J.; Xiao, D.; Degrado, S.; et al. Discovery of Sch 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia. ACS Med. Chem. Lett. 2012, 3, 63-68.
401. Shen, H. C.; Taggart, A. K. P.; Wilsie, L. C.; Waters, M. G.; Hammond, M. L.; Tata, J. R.; Colletti, S. L. Discovery of Pyrazolopyrimidines as the First Class of Allosteric Agonists for the High Affinity Nicotinic Acid Receptor GPR109A. Bioorg. Med. Chem. Lett. 2008, 18, 4948-4951.
402. Tunaru, S.; Lattig, J.; Kero, J.; Krause, G.; Offermanns, S. Characterization of Determinants of Ligand Binding to the Nicotinic Acid Receptor GPR109a (HM74a/PUMA-G). Mol. Pharmacol. 2005, 68, 1271-1280.